<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-id journal-id-type="iso-abbrev">Respir Res</journal-id><journal-id journal-id-type="pmc-domain-id">80</journal-id><journal-id journal-id-type="pmc-domain">rr</journal-id><journal-title-group><journal-title>Respiratory Research</journal-title></journal-title-group><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12243364</article-id><article-id pub-id-type="pmcid-ver">PMC12243364.1</article-id><article-id pub-id-type="pmcaid">12243364</article-id><article-id pub-id-type="pmcaiid">12243364</article-id><article-id pub-id-type="pmid">40640812</article-id><article-id pub-id-type="doi">10.1186/s12931-025-03317-3</article-id><article-id pub-id-type="publisher-id">3317</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Serum &#947;-glutamyl transferase as a novel risk indicator for lung cancer: insights from four million Koreans</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5643-6095</contrib-id><name name-style="western"><surname>Chung</surname><given-names initials="C">Chiwook</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="KN">Kyu Na</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8128-8920</contrib-id><name name-style="western"><surname>Shin</surname><given-names initials="DW">Dong Wook</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4814-6730</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="SW">Sei Won</given-names></name><address><email>iseiwon@gmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9622-0643</contrib-id><name name-style="western"><surname>Han</surname><given-names initials="K">Kyungdo</given-names></name><address><email>hkd917@naver.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04n278m24</institution-id><institution-id institution-id-type="GRID">grid.488450.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1790 2596</institution-id><institution>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, </institution><institution>Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, </institution></institution-wrap>Hwaseong, Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017xnm587</institution-id><institution-id institution-id-type="GRID">grid.263765.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0533 3568</institution-id><institution>Department of Statistics and Actuarial Science, </institution><institution>Soongsil University, </institution></institution-wrap>Sangdo- ro 369, Dongjak-gu, Seoul, 06978 Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04q78tk20</institution-id><institution-id institution-id-type="GRID">grid.264381.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 989X</institution-id><institution>Department of Family Medicine, </institution><institution>Samsung Medical Center, Sungkyunkwan University School of Medicine, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04q78tk20</institution-id><institution-id institution-id-type="GRID">grid.264381.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 989X</institution-id><institution>Department of Clinical Research Design and Evaluation, </institution><institution>Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02c2f8975</institution-id><institution-id institution-id-type="GRID">grid.267370.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0533 4667</institution-id><institution>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, </institution><institution>University of Ulsan College of Medicine, </institution></institution-wrap>88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">478376</issue-id><elocation-id>242</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-12 10:25:32.810"><day>12</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12931_2025_Article_3317.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">&#947;-glutamyl transferase (GGT) is associated with carcinogenesis, cancer progression, and metastasis. We investigated associations between serum GGT levels and lung cancer in the Korean general population.</p></sec><sec><title>Methods</title><p id="Par2">Individuals participating in the national health examination in 2012 were screened in the Korean National Health Information Database. Overall, 2,414,755 males and 2,032,241 females aged&#8201;&#8805;&#8201;20 years were followed up until December 2022. Of these individuals, 25,728 males and 11,706 females were diagnosed with lung cancer based on health-insurance claims. Serum GGT levels were categorized into quartiles Q1 (low)&#8211;Q4 (high) or deciles D1 (low)&#8211;D10 (high). Multivariate Cox proportional hazard models were used to estimate the adjusted hazard ratio (aHR) of risk factors for lung cancer.</p></sec><sec><title>Results</title><p id="Par3">In quartile categories, the highest quartile of serum GGT levels (Q4, males: &#8805;54 IU/L; females: &#8805;24 IU/L) had the highest incidence (males: 1.24/1,000 person-years; females: 0.79/1,000 person-years) and risk (males: aHR 1.37, 95% confidence interval [CI] 1.32&#8211;1.42; females: aHR 1.13, 95% CI 1.06&#8211;1.19) of lung cancer. In the decile categories, the incidence and risk of lung cancer increased with increasing serum GGT levels, resulting in the highest risk of lung cancer in the D10 category (males: &#8805;93 IU/L, aHR 1.57, 95% CI 1.48&#8211;1.67; females: &#8805;37 IU/L, aHR 1.20, 95% CI 1.10&#8211;1.31). Stratified analyses identified age (middle-aged/older adults), smoking status (never/former smokers), or alcohol consumption (non/mild alcohol drinkers [&lt;&#8201;10&#160;g/day]) to be prominently associated with higher lung cancer risks.</p></sec><sec><title>Conclusions</title><p id="Par4">Increased serum levels of GGT correlated with higher risk of lung cancer, even after adjusting for smoking status, alcohol consumption, and chronic liver disease. These effects were more prominent in never/former smokers and in non/mild alcohol drinkers.</p></sec><sec><title>Clinical trial number</title><p id="Par5">not applicable.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>GGT</kwd><kwd>Lung cancer</kwd><kwd>Smoking</kwd><kwd>Alcohol consumption</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Institute of Health research project</institution></funding-source><award-id>2024ER080600</award-id><principal-award-recipient><name name-style="western"><surname>Lee</surname><given-names>Sei Won</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>RS-2023-NR077159</award-id><principal-award-recipient><name name-style="western"><surname>Lee</surname><given-names>Sei Won</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Lung cancer is a common cancer and a major cancer-related cause of mortality worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. In 2021, lung cancer became the most common cancer in males and fourth most common in females (crude incidence rate: 82.1/100,000 and 42.1/100,000, respectively) in Korea. Moreover, lung cancer was the leading cause of death in both males and females (crude mortality rate: 52.7/100,000 and 18.4/100,000, respectively) [<xref ref-type="bibr" rid="CR2">2</xref>]. With the increasing burden of lung cancer, the need for reliable tumor markers also increases to ensure early detection and prognosis assessment. Unfortunately, several available tumor markers, including the cytokeratin 19 fragment (Cyfra 21&#8201;&#8722;&#8201;1), neuron-specific enolase (NSE), progastrin-releasing peptide (ProGRP), squamous cell carcinoma antigen (SCC), and carcinoembryonic antigen (CEA), have shown limited sensitivity and specificity (50&#8211;60%) for use in clinical practice [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par7">Gamma-glutamyl transferase (GGT) is a key enzyme in serum glutathione metabolism and plays an important role in antioxidant defense mechanisms [<xref ref-type="bibr" rid="CR4">4</xref>]. Elevated serum GGT levels have been proposed as a surrogate marker of oxidative stress in several diseases, including cancer, lung inflammation, and cardiovascular and neurogenic diseases [<xref ref-type="bibr" rid="CR5">5</xref>]. GGT also plays a potentially important role in carcinogenesis, cancer progression, metastasis, and drug resistance [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Observational studies have shown associations between elevated GGT levels and the risk of developing lung cancer [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Furthermore, elevated GGT levels have been linked to poor prognosis in patients with both surgically treated early-stage and metastatic lung cancer [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par8">Although previous studies have shown an association between serum GGT level and lung cancer, they presented limitations in their study design, including not considering the smoking history of patients [<xref ref-type="bibr" rid="CR8">8</xref>], a limited number of covariates in multivariate models (such as age, sex, socioeconomic status, and history of circulatory disease) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], potential surveillance bias or reverse causality [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], limited follow-up duration [<xref ref-type="bibr" rid="CR9">9</xref>], and uncertain cancer outcome definition [<xref ref-type="bibr" rid="CR12">12</xref>]. Thus, we investigated the association between serum GGT levels and lung cancer development in the Korean general population. To overcome limitations of previous studies, we designed multivariate regression models (1) adjusting for demographics, lifestyle behaviors, and comorbidities; (2) minimizing surveillance bias or reverse causality; and (3) defining valid cancer outcomes [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Cigarette smoking and alcohol consumption are well-known risk factors of lung cancer and are lifestyle behaviors more prevalent in males [<xref ref-type="bibr" rid="CR17">17</xref>]; higher exposure to these factors have a synergistic augmenting effect on serum GGT levels [<xref ref-type="bibr" rid="CR18">18</xref>]. Thus, in this study, we conducted separate statistical analyses for males and females to minimize potential confounders.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source</title><p id="Par9">The Korean National Health Information Database is a public database constructed by the Korean National Health Insurance Service (NHIS), which provides data on the sociodemographic characteristics, national health examination (NHE), healthcare use and insurance claims, and mortality of the entire Korean population (~&#8201;50&#160;million) since 2001 [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The NHIS is a single insurer and a mandatory universal public health insurance system covering 97% of the Korean population, whereas the remaining 3% in the lowest income bracket is covered by the public assistance system, Medical aid. However, the NHIS is involved in the administrative processes for Medical aid beneficiaries.</p><p id="Par10">The NHIS has provided an NHE program for the prevention and early detection of diseases since 1995 [<xref ref-type="bibr" rid="CR21">21</xref>]. Until 2018, adult employees aged&#8201;&#8805;&#8201;19 years or adults aged&#8201;&#8805;&#8201;40 years with national health insurance underwent the NHE biannually (annually for manual workers), including simple chest radiography, laboratory tests, and self-report questionnaires about lifestyle behaviors and medical history [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec4"><title>Study population</title><p id="Par11">We sampled 40% (4,910,068) of the individuals who received an NHE in 2012 (the index year). Of these individuals, 2,675,403 males and 2,234,665 females were selected. Thereafter, we excluded 52,403 males and 67,521 females with any insurance-claims data with the International Classification of Diseases 10th Revision (ICD-10) codes for cancer (C00&#8211;C97) and critical illness registration (code for cancer V193) before their health examination (all cancer wash-out), 184,208 males and 113,929 females with insufficient medical records, and 24,037 males and 20,974 females with any insurance claim for cancer (ICD-10 codes C00&#8211;C97) and critical illness registration (code V193) within 1 year after the index date (1-year lag period). The cancer wash-out and 1-year lag period were designed to minimize the potential over-detection of lung cancer (surveillance bias). Finally, the remaining 2,414,755 males and 2,032,241 females were included in this study, and follow-up was started at 1 year after the index date. The follow-up continued until December 2022 and ended at lung-cancer identification (study outcome), death, or censoring (such as out-migration). The mean follow-up duration was 9.29&#8201;&#177;&#8201;0.89 years. Consequently, 25,728 males and 11,706 females were identified with newly developed lung cancer (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par12">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flowchart</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e374" position="float" orientation="portrait" xlink:href="12931_2025_3317_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>Study outcome and main exposure</title><p id="Par13">The outcome of this study was new lung cancer development, which was identified using insurance claims for lung cancer (ICD-10 codes C33 and C34) and matched with the critical illness registration program data (special code V193 for cancer). The NHIS provides a 95% special copayment deduction (cancer diagnosis and treatment for 5 years) for patients with any type of cancer. To provide copayment deduction, the NHIS reviews the cancer diagnosis certificates submitted by attending physicians and registers them in the critical illness registration program. Given the current system, these matched data provide highly accurate cancer diagnosis in Korea [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par14">The main exposure of this study was a serum GGT level (IU/L). Laboratory tests during NHEs include hemoglobin, serum creatinine, fasting glucose, aspartate aminotransferase, alanine aminotransferase, GGT, and lipid profiles. Serum GGT levels were categorized into quartiles Q1 (low)&#8211;Q4 (high) or deciles D1 (low)&#8211;D10 (high).</p></sec><sec id="Sec6"><title>Covariates</title><p id="Par15">Anthropometric measurements (body weight, height, waist circumference, and blood pressure) and lifestyle behaviors from self-reported questionnaires (cigarette smoking, alcohol consumption, and physical activity) were collected from the NHE. Body mass index (BMI) was calculated by dividing body weight by height squared (kg/m<sup>2</sup>). Cigarette smoking was categorized as never, former, and current smokers. Alcohol consumption was categorized into non, mild (&lt;&#8201;10&#160;g alcohol/day), moderate (10&#8211;19&#160;g alcohol/day) and heavy (&#8805;&#8201;20&#160;g alcohol/day) drinkers. Regular exercise was defined as &gt;&#8201;30&#160;min of moderate physical activity at least five times weekly or &gt;&#8201;20&#160;min of vigorous physical activity at least three times weekly [<xref ref-type="bibr" rid="CR23">23</xref>]. Income level was categorized into quartiles (Q1&#8211;Q4, from lowest to highest); Medical aid beneficiaries were also included in the Q1 category.</p><p id="Par16">Comorbidities were identified based on the NHIS and NHE data within 1 year before the index date according to the following definitions: (1) diabetes, either insurance claims for ICD-10 codes E11&#8211;14 with prescriptions of hypoglycemic medications or a fasting serum glucose level&#8201;&#8805;&#8201;126&#160;mg/dL in a health examination; (2) hypertension, either insurance claims for ICD-10 codes I10&#8211;13 and I15 with prescriptions of antihypertensive medications or high blood pressure (systolic blood pressure&#8201;&#8805;&#8201;140 mmHg or diastolic blood pressure&#8201;&#8805;&#8201;90 mmHg) measured during a health examination; (3) dyslipidemia, either insurance claims for ICD-10 code E78 with prescriptions of lipid-lowering medications or serum total cholesterol level&#8201;&#8805;&#8201;240&#160;mg/dL during a health examination; (4) chronic kidney disease, either insurance claims for ICD-10 codes N18&#8211;19 or an estimated glomerular filtration rate&#8201;&lt;&#8201;60 mL/min/1.73 m<sup>2</sup> by the Modification of Diet in Renal Disease equation during a health examination; (5) liver cirrhosis, insurance claims for ICD-10 codes K70.3 and K74.6; (6) viral hepatitis, insurance claims for ICD-10 codes B15&#8211;19; and (7) alcohol use disorder, insurance claims for ICD-10 codes F10.</p><p id="Par17">Individuals were classified as having metabolic syndrome, if they met at least three of the following five diagnostic criteria: (1) abdominal obesity, defined as a waist circumference of &#8805;&#8201;90&#160;cm for males or &#8805;&#8201;85&#160;cm for females; (2) hyperglycemia, indicated by a fasting serum glucose level of &#8805;&#8201;100&#160;mg/dL or the prescription of hypoglycemic medications; (3) hypertension, defined as systolic/diastolic blood pressure of &#8805;&#8201;130/85 mmHg or antihypertensive treatment; (4) hypertriglyceridemia, with triglyceride levels of &#8805;&#8201;150&#160;mg/dL or corresponding medical treatment; and (5) reduced levels of high-density lipoprotein cholesterol, defined as &lt;&#8201;40&#160;mg/dL in males or &lt;&#8201;50&#160;mg/dL in females, or the use of lipid-lowering treatment [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par18">Continuous variables are expressed as means&#8201;&#177;&#8201;standard deviation (SD) and were compared using analysis of variance. Categorical variables are reported as numbers (percentages) and were compared using the &#967;<sup>2</sup> test. The lung cancer incidence rate was calculated as the ratio between the number of patients with newly diagnosed lung cancer and the number of person-years (PY) at risk of developing lung cancer (per 1,000). The cumulative lung cancer incidence was demonstrated through Kaplan&#8211;Meier survival analysis. A multivariate Cox proportional hazards model was constructed to evaluate the effect of risk factors on the time-to-event of lung cancer development. The proportional hazards assumption was checked using the Schoenfeld residuals test. Model 1 was non-adjusted. In Model 2, the covariates included age. Model 3 included the covariates in Model 2, along with income, BMI, cigarette smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, and chronic kidney disease. Model 4 (the main analysis model) included the covariates in Model 3, along with liver cirrhosis, viral hepatitis, alcohol-use disorder, and metabolic syndrome. These variables were added in the final model to adjust for the potential influence of chronic liver diseases and metabolic disorders that may affect GGT levels. Subgroup analysis stratified by age, cigarette smoking (smoking status and amount), and alcohol consumption was performed for Model 3. Smoking amount was measured by pack-year (1 pack-year: 20 cigarettes smoked daily for 1 year), and categorized by 10 pack-years (never, 1&#8211;9, 10&#8211;19, and &#8805;&#8201;20 pack-years). Restricted cubic spline curve was employed to describe the relationship between GGT level and lung cancer risk. All <italic toggle="yes">P</italic> values were two-tailed, and statistical significance was set at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05. All statistical analyses were conducted using SAS v.9.4 (SAS Institute, Cary, NC, USA), and the PHREG procedure was used for the Cox proportional hazards model.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Baseline characteristics</title><p id="Par19">Tables&#160;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> summarizes the baseline characteristics of the study population stratified by the serum GGT level categories. The mean age of all participants was 48.0&#8201;&#177;&#8201;13.7 years. Among the participants, 59.6% were never smokers, and 50.5% were non-alcohol drinkers. Most female participants were never smokers (&gt;&#8201;90% across all categories) and non-alcohol drinkers (&gt;&#8201;70% across all categories). In contrast, approximately 30% of male participants were never smokers and non-alcohol drinkers, with these proportions decreasing across higher GGT level categories.</p><p id="Par20">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the male study population stratified by serum &#947;-glutamyl transferase (GGT) levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">Q1 (&#8804;&#8201;21 IU/L)</th><th align="left" colspan="1" rowspan="1">Q2 (22&#8211;31 IU/L)</th><th align="left" colspan="1" rowspan="1">Q3 (32&#8211;53IU/L)</th><th align="left" colspan="1" rowspan="1">Q4 (&#8805;&#8201;54 IU/L)</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2,414,755</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;628,854</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;575,468</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;613,223</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;597,210</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">46.7&#8201;&#177;&#8201;13.2</td><td align="left" colspan="1" rowspan="1">45.8&#8201;&#177;&#8201;14.9</td><td align="left" colspan="1" rowspan="1">47.0&#8201;&#177;&#8201;13.6</td><td align="left" colspan="1" rowspan="1">47.2&#8201;&#177;&#8201;12.6</td><td align="left" colspan="1" rowspan="1">47.0&#8201;&#177;&#8201;11.5</td></tr><tr><td align="left" colspan="1" rowspan="1">20&#8211;39 years</td><td align="left" colspan="1" rowspan="1">784,357 (32.5)</td><td align="left" colspan="1" rowspan="1">248,421 (39.5)</td><td align="left" colspan="1" rowspan="1">189,546 (32.9)</td><td align="left" colspan="1" rowspan="1">183,580 (29.9)</td><td align="left" colspan="1" rowspan="1">162,810 (27.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;64 years</td><td align="left" colspan="1" rowspan="1">1,376,556 (57.0)</td><td align="left" colspan="1" rowspan="1">298,082 (47.4)</td><td align="left" colspan="1" rowspan="1">318,536 (55.4)</td><td align="left" colspan="1" rowspan="1">370,071 (60.4)</td><td align="left" colspan="1" rowspan="1">389,867 (65.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;65 years</td><td align="left" colspan="1" rowspan="1">253,842 (10.5)</td><td align="left" colspan="1" rowspan="1">82,351 (13.1)</td><td align="left" colspan="1" rowspan="1">67,386 (11.7)</td><td align="left" colspan="1" rowspan="1">59,572 (9.7)</td><td align="left" colspan="1" rowspan="1">44,533 (7.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Income, lowest Q1</td><td align="left" colspan="1" rowspan="1">327,915 (13.6)</td><td align="left" colspan="1" rowspan="1">88,214 (14.0)</td><td align="left" colspan="1" rowspan="1">76,241 (13.3)</td><td align="left" colspan="1" rowspan="1">80,193 (13.1)</td><td align="left" colspan="1" rowspan="1">83,267 (13.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup></td><td align="left" colspan="1" rowspan="1">24.3&#8201;&#177;&#8201;3.1</td><td align="left" colspan="1" rowspan="1">22.9&#8201;&#177;&#8201;2.7</td><td align="left" colspan="1" rowspan="1">24.0&#8201;&#177;&#8201;2.8</td><td align="left" colspan="1" rowspan="1">24.9&#8201;&#177;&#8201;3.0</td><td align="left" colspan="1" rowspan="1">25.4&#8201;&#177;&#8201;3.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Waist circumference, cm</td><td align="left" colspan="1" rowspan="1">83.8&#8201;&#177;&#8201;8.0</td><td align="left" colspan="1" rowspan="1">80.1&#8201;&#177;&#8201;7.2</td><td align="left" colspan="1" rowspan="1">82.9&#8201;&#177;&#8201;7.5</td><td align="left" colspan="1" rowspan="1">85.3&#8201;&#177;&#8201;7.6</td><td align="left" colspan="1" rowspan="1">86.9&#8201;&#177;&#8201;7.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Non-smoker</td><td align="left" colspan="1" rowspan="1">728,494 (30.2)</td><td align="left" colspan="1" rowspan="1">248,181 (39.5)</td><td align="left" colspan="1" rowspan="1">186,898 (32.5)</td><td align="left" colspan="1" rowspan="1">166,023 (27.1)</td><td align="left" colspan="1" rowspan="1">127,392 (21.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Former</td><td align="left" colspan="1" rowspan="1">650,510 (26.9)</td><td align="left" colspan="1" rowspan="1">162,896 (25.9)</td><td align="left" colspan="1" rowspan="1">160,147 (27.8)</td><td align="left" colspan="1" rowspan="1">171,682 (28.0)</td><td align="left" colspan="1" rowspan="1">155,785 (26.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current</td><td align="left" colspan="1" rowspan="1">1,035,751 (42.9)</td><td align="left" colspan="1" rowspan="1">217,777 (34.6)</td><td align="left" colspan="1" rowspan="1">228,423 (39.7)</td><td align="left" colspan="1" rowspan="1">275,518 (44.9)</td><td align="left" colspan="1" rowspan="1">314,033 (52.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcohol consumption</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">759,039 (31.4)</td><td align="left" colspan="1" rowspan="1">288,723 (45.9)</td><td align="left" colspan="1" rowspan="1">209,447 (36.4)</td><td align="left" colspan="1" rowspan="1">166,656 (27.2)</td><td align="left" colspan="1" rowspan="1">94,213 (15.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild (&lt;&#8201;10&#160;g/day)</td><td align="left" colspan="1" rowspan="1">683,476 (28.3)</td><td align="left" colspan="1" rowspan="1">205,615 (32.7)</td><td align="left" colspan="1" rowspan="1">180,370 (31.3)</td><td align="left" colspan="1" rowspan="1">172,949 (28.2)</td><td align="left" colspan="1" rowspan="1">124,542 (20.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderate (10&#8211;19&#160;g/day)</td><td align="left" colspan="1" rowspan="1">425,686 (17.6)</td><td align="left" colspan="1" rowspan="1">78,076 (12.4)</td><td align="left" colspan="1" rowspan="1">95,498 (16.6)</td><td align="left" colspan="1" rowspan="1">123,048 (20.1)</td><td align="left" colspan="1" rowspan="1">129,064 (21.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy (&#8805;&#8201;20&#160;g/day)</td><td align="left" colspan="1" rowspan="1">546,554 (22.6)</td><td align="left" colspan="1" rowspan="1">56,440 (9.0)</td><td align="left" colspan="1" rowspan="1">90,153 (15.7)</td><td align="left" colspan="1" rowspan="1">150,570 (24.6)</td><td align="left" colspan="1" rowspan="1">249,391 (41.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Regular exercise</td><td align="left" colspan="1" rowspan="1">509,123 (21.1)</td><td align="left" colspan="1" rowspan="1">145,705 (23.2)</td><td align="left" colspan="1" rowspan="1">125,707 (21.8)</td><td align="left" colspan="1" rowspan="1">125,425 (20.5)</td><td align="left" colspan="1" rowspan="1">112,286 (18.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1">268,402 (11.1)</td><td align="left" colspan="1" rowspan="1">45,857 (7.3)</td><td align="left" colspan="1" rowspan="1">53,432 (9.3)</td><td align="left" colspan="1" rowspan="1">72,764 (11.9)</td><td align="left" colspan="1" rowspan="1">96,349 (16.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">684,705 (28.4)</td><td align="left" colspan="1" rowspan="1">119,950 (19.1)</td><td align="left" colspan="1" rowspan="1">144,393 (25.1)</td><td align="left" colspan="1" rowspan="1">189,453 (30.9)</td><td align="left" colspan="1" rowspan="1">230,909 (38.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">452,383 (18.7)</td><td align="left" colspan="1" rowspan="1">63,258 (10.1)</td><td align="left" colspan="1" rowspan="1">92,224 (16.0)</td><td align="left" colspan="1" rowspan="1">131,833 (21.5)</td><td align="left" colspan="1" rowspan="1">165,068 (27.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic kidney disease</td><td align="left" colspan="1" rowspan="1">68,750 (2.9)</td><td align="left" colspan="1" rowspan="1">17,050 (2.7)</td><td align="left" colspan="1" rowspan="1">17,600 (3.1)</td><td align="left" colspan="1" rowspan="1">18,583 (3.0)</td><td align="left" colspan="1" rowspan="1">15,517 (2.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver cirrhosis</td><td align="left" colspan="1" rowspan="1">7,796 (0.3)</td><td align="left" colspan="1" rowspan="1">1,245 (0.2)</td><td align="left" colspan="1" rowspan="1">1,374 (0.2)</td><td align="left" colspan="1" rowspan="1">1,751 (0.3)</td><td align="left" colspan="1" rowspan="1">3,426 (0.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Viral hepatitis</td><td align="left" colspan="1" rowspan="1">68,310 (2.8)</td><td align="left" colspan="1" rowspan="1">17,250 (2.7)</td><td align="left" colspan="1" rowspan="1">15,597 (2.7)</td><td align="left" colspan="1" rowspan="1">16,705 (2.7)</td><td align="left" colspan="1" rowspan="1">18,758 (3.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic use disorder</td><td align="left" colspan="1" rowspan="1">9,744 (0.4)</td><td align="left" colspan="1" rowspan="1">1,520 (0.2)</td><td align="left" colspan="1" rowspan="1">1,705 (0.3)</td><td align="left" colspan="1" rowspan="1">2,266 (0.4)</td><td align="left" colspan="1" rowspan="1">4,253 (0.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metabolic syndrome</td><td align="left" colspan="1" rowspan="1">681,299 (28.2)</td><td align="left" colspan="1" rowspan="1">82,176 (13.1)</td><td align="left" colspan="1" rowspan="1">127,904 (22.2)</td><td align="left" colspan="1" rowspan="1">200,000 (32.6)</td><td align="left" colspan="1" rowspan="1">271,219 (45.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol</td><td align="left" colspan="1" rowspan="1">194.2&#8201;&#177;&#8201;36.1</td><td align="left" colspan="1" rowspan="1">181.9&#8201;&#177;&#8201;32.1</td><td align="left" colspan="1" rowspan="1">192.3&#8201;&#177;&#8201;33.8</td><td align="left" colspan="1" rowspan="1">198.8&#8201;&#177;&#8201;35.5</td><td align="left" colspan="1" rowspan="1">204.4&#8201;&#177;&#8201;38.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting blood glucose</td><td align="left" colspan="1" rowspan="1">99.8&#8201;&#177;&#8201;25.0</td><td align="left" colspan="1" rowspan="1">94.7&#8201;&#177;&#8201;19.6</td><td align="left" colspan="1" rowspan="1">97.6&#8201;&#177;&#8201;22.2</td><td align="left" colspan="1" rowspan="1">100.9&#8201;&#177;&#8201;25.4</td><td align="left" colspan="1" rowspan="1">106.1&#8201;&#177;&#8201;30.2</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#8201;&#177;&#8201;standard deviation (SD) or number (%), unless otherwise indicated</p><p>BMI, body mass index</p></table-wrap-foot></table-wrap>
</p><p id="Par21">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Baseline characteristics of the female study population stratified by serum &#947;-glutamyl transferase (GGT) levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">Q1 (&#8804;&#8201;12 IU/L)</th><th align="left" colspan="1" rowspan="1">Q2 (13&#8211;16 IU/L)</th><th align="left" colspan="1" rowspan="1">Q3 (17&#8211;23IU/L)</th><th align="left" colspan="1" rowspan="1">Q4 (&#8805;&#8201;24 IU/L)</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2,032,241</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;505,706</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;517,483</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;503,525</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;505,527</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">49.4&#8201;&#177;&#8201;14.2</td><td align="left" colspan="1" rowspan="1">44.9&#8201;&#177;&#8201;14.1</td><td align="left" colspan="1" rowspan="1">48.1&#8201;&#177;&#8201;14.4</td><td align="left" colspan="1" rowspan="1">51.3&#8201;&#177;&#8201;14.0</td><td align="left" colspan="1" rowspan="1">53.5&#8201;&#177;&#8201;12.6</td></tr><tr><td align="left" colspan="1" rowspan="1">20&#8211;39 years</td><td align="left" colspan="1" rowspan="1">465,906 (22.9)</td><td align="left" colspan="1" rowspan="1">175,072 (34.6)</td><td align="left" colspan="1" rowspan="1">137,468 (26.6)</td><td align="left" colspan="1" rowspan="1">93,907 (18.7)</td><td align="left" colspan="1" rowspan="1">59,459 (11.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;64 years</td><td align="left" colspan="1" rowspan="1">1,259,943 (62.0)</td><td align="left" colspan="1" rowspan="1">279,704 (55.3)</td><td align="left" colspan="1" rowspan="1">308,446 (59.6)</td><td align="left" colspan="1" rowspan="1">320,494 (63.7)</td><td align="left" colspan="1" rowspan="1">351,299 (69.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;65 years</td><td align="left" colspan="1" rowspan="1">306,392 (15.1)</td><td align="left" colspan="1" rowspan="1">50,930 (10.1)</td><td align="left" colspan="1" rowspan="1">71,569 (13.8)</td><td align="left" colspan="1" rowspan="1">89,124 (17.7)</td><td align="left" colspan="1" rowspan="1">94,769 (18.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Income, lowest Q1</td><td align="left" colspan="1" rowspan="1">501,912 (24.7)</td><td align="left" colspan="1" rowspan="1">118,673 (23.5)</td><td align="left" colspan="1" rowspan="1">125,170 (24.2)</td><td align="left" colspan="1" rowspan="1">125,490 (24.9)</td><td align="left" colspan="1" rowspan="1">132,579 (26.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup></td><td align="left" colspan="1" rowspan="1">23.2&#8201;&#177;&#8201;3.4</td><td align="left" colspan="1" rowspan="1">22.0&#8201;&#177;&#8201;2.8</td><td align="left" colspan="1" rowspan="1">22.6&#8201;&#177;&#8201;3.1</td><td align="left" colspan="1" rowspan="1">23.5&#8201;&#177;&#8201;3.4</td><td align="left" colspan="1" rowspan="1">24.6&#8201;&#177;&#8201;3.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Waist circumference, cm</td><td align="left" colspan="1" rowspan="1">76.1&#8201;&#177;&#8201;9.0</td><td align="left" colspan="1" rowspan="1">72.8&#8201;&#177;&#8201;7.8</td><td align="left" colspan="1" rowspan="1">74.6&#8201;&#177;&#8201;8.3</td><td align="left" colspan="1" rowspan="1">77.0&#8201;&#177;&#8201;8.9</td><td align="left" colspan="1" rowspan="1">80.2&#8201;&#177;&#8201;9.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Non-smoker</td><td align="left" colspan="1" rowspan="1">1,922,373 (94.6)</td><td align="left" colspan="1" rowspan="1">487,055 (96.3)</td><td align="left" colspan="1" rowspan="1">494,543 (95.6)</td><td align="left" colspan="1" rowspan="1">476,185 (94.6)</td><td align="left" colspan="1" rowspan="1">464,590 (91.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Former</td><td align="left" colspan="1" rowspan="1">37,464 (1.8)</td><td align="left" colspan="1" rowspan="1">8,393 (1.7)</td><td align="left" colspan="1" rowspan="1">8,892 (1.7)</td><td align="left" colspan="1" rowspan="1">9,252 (1.8)</td><td align="left" colspan="1" rowspan="1">10,927 (2.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current</td><td align="left" colspan="1" rowspan="1">72,404 (3.6)</td><td align="left" colspan="1" rowspan="1">10,258 (2.0)</td><td align="left" colspan="1" rowspan="1">14,048 (2.7)</td><td align="left" colspan="1" rowspan="1">18,088 (3.6)</td><td align="left" colspan="1" rowspan="1">30,010 (5.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcohol consumption</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">1,487,875 (73.2)</td><td align="left" colspan="1" rowspan="1">380,409 (75.2)</td><td align="left" colspan="1" rowspan="1">379,838 (73.4)</td><td align="left" colspan="1" rowspan="1">368,374 (73.2)</td><td align="left" colspan="1" rowspan="1">359,254 (71.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild (&lt;&#8201;10&#160;g/day)</td><td align="left" colspan="1" rowspan="1">415,133 (20.4)</td><td align="left" colspan="1" rowspan="1">107,126 (21.2)</td><td align="left" colspan="1" rowspan="1">111,255 (21.5)</td><td align="left" colspan="1" rowspan="1">101,956 (20.3)</td><td align="left" colspan="1" rowspan="1">94,796 (18.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderate (10&#8211;19&#160;g/day)</td><td align="left" colspan="1" rowspan="1">79,246 (3.9)</td><td align="left" colspan="1" rowspan="1">12,743 (2.5)</td><td align="left" colspan="1" rowspan="1">17,546 (3.4)</td><td align="left" colspan="1" rowspan="1">20,717 (4.1)</td><td align="left" colspan="1" rowspan="1">28,240 (5.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy (&#8805;&#8201;20&#160;g/day)</td><td align="left" colspan="1" rowspan="1">49,987 (2.5)</td><td align="left" colspan="1" rowspan="1">5,428 (1.1)</td><td align="left" colspan="1" rowspan="1">8,844 (1.7)</td><td align="left" colspan="1" rowspan="1">12,478 (2.5)</td><td align="left" colspan="1" rowspan="1">23,237 (4.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Regular exercise</td><td align="left" colspan="1" rowspan="1">336,367 (16.6)</td><td align="left" colspan="1" rowspan="1">81,684 (16.2)</td><td align="left" colspan="1" rowspan="1">85,876 (16.6)</td><td align="left" colspan="1" rowspan="1">85,406 (17.0)</td><td align="left" colspan="1" rowspan="1">83,401 (16.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1">168,753 (8.3)</td><td align="left" colspan="1" rowspan="1">18,011 (3.6)</td><td align="left" colspan="1" rowspan="1">28,290 (5.5)</td><td align="left" colspan="1" rowspan="1">44,652 (8.9)</td><td align="left" colspan="1" rowspan="1">77,800 (15.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">519,848 (25.6)</td><td align="left" colspan="1" rowspan="1">69,801 (13.8)</td><td align="left" colspan="1" rowspan="1">105,380 (20.4)</td><td align="left" colspan="1" rowspan="1">146,752 (29.1)</td><td align="left" colspan="1" rowspan="1">197,915 (39.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">448,211 (22.1)</td><td align="left" colspan="1" rowspan="1">55,118 (10.9)</td><td align="left" colspan="1" rowspan="1">87,853 (17.0)</td><td align="left" colspan="1" rowspan="1">127,141 (25.3)</td><td align="left" colspan="1" rowspan="1">178,099 (35.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic kidney disease</td><td align="left" colspan="1" rowspan="1">95,683 (4.7)</td><td align="left" colspan="1" rowspan="1">14,105 (2.8)</td><td align="left" colspan="1" rowspan="1">21,026 (4.1)</td><td align="left" colspan="1" rowspan="1">27,511 (5.5)</td><td align="left" colspan="1" rowspan="1">33,041 (6.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver cirrhosis</td><td align="left" colspan="1" rowspan="1">3,235 (0.2)</td><td align="left" colspan="1" rowspan="1">373 (0.1)</td><td align="left" colspan="1" rowspan="1">522 (0.1)</td><td align="left" colspan="1" rowspan="1">691 (0.1)</td><td align="left" colspan="1" rowspan="1">1,649 (0.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Viral hepatitis</td><td align="left" colspan="1" rowspan="1">53,203 (2.6)</td><td align="left" colspan="1" rowspan="1">10,941 (2.2)</td><td align="left" colspan="1" rowspan="1">12,023 (2.3)</td><td align="left" colspan="1" rowspan="1">12,969 (2.6)</td><td align="left" colspan="1" rowspan="1">17,270 (3.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic use disorder</td><td align="left" colspan="1" rowspan="1">2,277 (0.1)</td><td align="left" colspan="1" rowspan="1">254 (0.1)</td><td align="left" colspan="1" rowspan="1">305 (0.1)</td><td align="left" colspan="1" rowspan="1">514 (0.1)</td><td align="left" colspan="1" rowspan="1">1,204 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metabolic syndrome</td><td align="left" colspan="1" rowspan="1">467,866 (23.0)</td><td align="left" colspan="1" rowspan="1">47,115 (9.3)</td><td align="left" colspan="1" rowspan="1">82,345 (15.9)</td><td align="left" colspan="1" rowspan="1">132,344 (26.3)</td><td align="left" colspan="1" rowspan="1">206,062 (40.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol</td><td align="left" colspan="1" rowspan="1">195.6&#8201;&#177;&#8201;37.1</td><td align="left" colspan="1" rowspan="1">185.8&#8201;&#177;&#8201;33.5</td><td align="left" colspan="1" rowspan="1">192.8&#8201;&#177;&#8201;34.8</td><td align="left" colspan="1" rowspan="1">198.9&#8201;&#177;&#8201;37.0</td><td align="left" colspan="1" rowspan="1">205.0&#8201;&#177;&#8201;39.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting blood glucose</td><td align="left" colspan="1" rowspan="1">95.3&#8201;&#177;&#8201;20.4</td><td align="left" colspan="1" rowspan="1">90.5&#8201;&#177;&#8201;13.8</td><td align="left" colspan="1" rowspan="1">92.7&#8201;&#177;&#8201;16.1</td><td align="left" colspan="1" rowspan="1">95.9&#8201;&#177;&#8201;19.7</td><td align="left" colspan="1" rowspan="1">101.9&#8201;&#177;&#8201;27.4</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#8201;&#177;&#8201;standard deviation (SD) or number (%), unless otherwise indicated</p><p>BMI, body mass index</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Risk of lung cancer according to serum GGT levels</title><p id="Par22">Tables&#160;<xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref> present associations between serum GGT levels and lung cancer development. Using the quartile categories, the incidence rate and risk of lung cancer increased with increasing GGT levels, resulting in the highest incidence rate (males: 1.24/1,00 PY; females: 0.79/1,000 PY) and risk (males: adjusted hazard ratio [aHR] 1.37, 95% confidence interval [CI] 1.32&#8211;1.42; females: aHR 1.13, 95% CI 1.06&#8211;1.19) in Q4 (males: &#8805;54 IU/L; females: &#8805;24 IU/L). The cumulative incidence of lung cancer increased in proportion to GGT levels and showed a consistent upward trend over time (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par23">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Associations between serum &#947;-glutamyl transferase (GGT) levels and lung-cancer development in male participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">GGT</th><th align="left" colspan="1" rowspan="1">N</th><th align="left" colspan="1" rowspan="1">Event</th><th align="left" colspan="1" rowspan="1">Duration, PY</th><th align="left" colspan="1" rowspan="1">IR, per 1000 PY</th><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Q1 (&#8804;&#8201;21 IU/L)</td><td align="left" colspan="1" rowspan="1">628,854</td><td align="left" colspan="1" rowspan="1">6,182</td><td align="left" colspan="1" rowspan="1">5,802,284</td><td align="left" colspan="1" rowspan="1">1.07</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q2 (22&#8211;31 IU/L)</td><td align="left" colspan="1" rowspan="1">575,468</td><td align="left" colspan="1" rowspan="1">6,188</td><td align="left" colspan="1" rowspan="1">5,306,828</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1.10 (1.06, 1.14)</td><td align="left" colspan="1" rowspan="1">1.15 (1.11, 1.19)</td><td align="left" colspan="1" rowspan="1">1.13 (1.09, 1.17)</td><td align="left" colspan="1" rowspan="1">1.13 (1.09, 1.17)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q3 (32&#8211;53 IU/L)</td><td align="left" colspan="1" rowspan="1">613,223</td><td align="left" colspan="1" rowspan="1">6,584</td><td align="left" colspan="1" rowspan="1">5,648,443</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1.10 (1.06, 1.14)</td><td align="left" colspan="1" rowspan="1">1.26 (1.22, 1.30)</td><td align="left" colspan="1" rowspan="1">1.22 (1.17, 1.26)</td><td align="left" colspan="1" rowspan="1">1.21 (1.17, 1.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q4 (&#8805;&#8201;54 IU/L)</td><td align="left" colspan="1" rowspan="1">597,210</td><td align="left" colspan="1" rowspan="1">6,774</td><td align="left" colspan="1" rowspan="1">5,461,995</td><td align="left" colspan="1" rowspan="1">1.24</td><td align="left" colspan="1" rowspan="1">1.17 (1.13, 1.21)</td><td align="left" colspan="1" rowspan="1">1.52 (1.46, 1.57)</td><td align="left" colspan="1" rowspan="1">1.39 (1.34, 1.44)</td><td align="left" colspan="1" rowspan="1">1.37 (1.32, 1.42)</td></tr><tr><td align="left" colspan="1" rowspan="1">D1 (&#8804;&#8201;15 IU/L)</td><td align="left" colspan="1" rowspan="1">218,370</td><td align="left" colspan="1" rowspan="1">2,072</td><td align="left" colspan="1" rowspan="1">2,012,404</td><td align="left" colspan="1" rowspan="1">1.03</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">D2 (16&#8211;19 IU/L)</td><td align="left" colspan="1" rowspan="1">269,222</td><td align="left" colspan="1" rowspan="1">2,651</td><td align="left" colspan="1" rowspan="1">2,485,905</td><td align="left" colspan="1" rowspan="1">1.07</td><td align="left" colspan="1" rowspan="1">1.04 (0.98, 1.10)</td><td align="left" colspan="1" rowspan="1">1.11 (1.05, 1.17)</td><td align="left" colspan="1" rowspan="1">1.10 (1.04, 1.17)</td><td align="left" colspan="1" rowspan="1">1.10 (1.04, 1.16)</td></tr><tr><td align="left" colspan="1" rowspan="1">D3 (20&#8211;22 IU/L)</td><td align="left" colspan="1" rowspan="1">209,427</td><td align="left" colspan="1" rowspan="1">2,172</td><td align="left" colspan="1" rowspan="1">1,932,973</td><td align="left" colspan="1" rowspan="1">1.12</td><td align="left" colspan="1" rowspan="1">1.09 (1.03, 1.16)</td><td align="left" colspan="1" rowspan="1">1.18 (1.11, 1.26)</td><td align="left" colspan="1" rowspan="1">1.17 (1.10, 1.24)</td><td align="left" colspan="1" rowspan="1">1.17 (1.10, 1.24)</td></tr><tr><td align="left" colspan="1" rowspan="1">D4 (23&#8211;26 IU/L)</td><td align="left" colspan="1" rowspan="1">250,030</td><td align="left" colspan="1" rowspan="1">2,708</td><td align="left" colspan="1" rowspan="1">2,305,986</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1.14 (1.08, 1.21)</td><td align="left" colspan="1" rowspan="1">1.24 (1.18, 1.32)</td><td align="left" colspan="1" rowspan="1">1.23 (1.16, 1.30)</td><td align="left" colspan="1" rowspan="1">1.22 (1.16, 1.30)</td></tr><tr><td align="left" colspan="1" rowspan="1">D5 (27&#8211;31 IU/L)</td><td align="left" colspan="1" rowspan="1">257,273</td><td align="left" colspan="1" rowspan="1">2,767</td><td align="left" colspan="1" rowspan="1">2,371,843</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1.14 (1.07, 1.20)</td><td align="left" colspan="1" rowspan="1">1.25 (1.18, 1.33)</td><td align="left" colspan="1" rowspan="1">1.22 (1.15, 1.30)</td><td align="left" colspan="1" rowspan="1">1.22 (1.15, 1.29)</td></tr><tr><td align="left" colspan="1" rowspan="1">D6 (32&#8211;37 IU/L)</td><td align="left" colspan="1" rowspan="1">232,981</td><td align="left" colspan="1" rowspan="1">2,574</td><td align="left" colspan="1" rowspan="1">2,146,166</td><td align="left" colspan="1" rowspan="1">1.20</td><td align="left" colspan="1" rowspan="1">1.17 (1.10, 1.24)</td><td align="left" colspan="1" rowspan="1">1.35 (1.27, 1.43)</td><td align="left" colspan="1" rowspan="1">1.30 (1.23, 1.38)</td><td align="left" colspan="1" rowspan="1">1.30 (1.22, 1.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">D7 (38&#8211;46 IU/L)</td><td align="left" colspan="1" rowspan="1">246,171</td><td align="left" colspan="1" rowspan="1">2,611</td><td align="left" colspan="1" rowspan="1">2,267,786</td><td align="left" colspan="1" rowspan="1">1.15</td><td align="left" colspan="1" rowspan="1">1.12 (1.06, 1.19)</td><td align="left" colspan="1" rowspan="1">1.36 (1.28, 1.44)</td><td align="left" colspan="1" rowspan="1">1.31 (1.23, 1.39)</td><td align="left" colspan="1" rowspan="1">1.30 (1.22, 1.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">D8 (47&#8211;61 IU/L)</td><td align="left" colspan="1" rowspan="1">249,343</td><td align="left" colspan="1" rowspan="1">2,627</td><td align="left" colspan="1" rowspan="1">2,295,444</td><td align="left" colspan="1" rowspan="1">1.14</td><td align="left" colspan="1" rowspan="1">1.11 (1.05, 1.18)</td><td align="left" colspan="1" rowspan="1">1.45 (1.37, 1.54)</td><td align="left" colspan="1" rowspan="1">1.38 (1.30, 1.47)</td><td align="left" colspan="1" rowspan="1">1.37 (1.29, 1.45)</td></tr><tr><td align="left" colspan="1" rowspan="1">D9 (62&#8211;92 IU/L)</td><td align="left" colspan="1" rowspan="1">240,856</td><td align="left" colspan="1" rowspan="1">2,537</td><td align="left" colspan="1" rowspan="1">2,212,887</td><td align="left" colspan="1" rowspan="1">1.15</td><td align="left" colspan="1" rowspan="1">1.12 (1.05, 1.18)</td><td align="left" colspan="1" rowspan="1">1.55 (1.46, 1.64)</td><td align="left" colspan="1" rowspan="1">1.45 (1.37, 1.54)</td><td align="left" colspan="1" rowspan="1">1.43 (1.35, 1.52)</td></tr><tr><td align="left" colspan="1" rowspan="1">D10 (&#8805;&#8201;93 IU/L)</td><td align="left" colspan="1" rowspan="1">241,082</td><td align="left" colspan="1" rowspan="1">3,009</td><td align="left" colspan="1" rowspan="1">2,188,156</td><td align="left" colspan="1" rowspan="1">1.38</td><td align="left" colspan="1" rowspan="1">1.34 (1.27, 1.42)</td><td align="left" colspan="1" rowspan="1">1.81 (1.71, 1.92)</td><td align="left" colspan="1" rowspan="1">1.60 (1.51, 1.70)</td><td align="left" colspan="1" rowspan="1">1.57 (1.48, 1.67)</td></tr></tbody></table><table-wrap-foot><p>Model 1: Non-adjusted</p><p>Model 2: Adjusted for age</p><p>Model 3: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, and chronic kidney disease</p><p>Model 4: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, chronic kidney disease, liver cirrhosis, viral hepatitis, alcohol use disorder, and metabolic syndrome</p><p>In the multivariate analyses, age and BMI were included as continuous variables</p><p>BMI, body mass index; CI, confidence interval; IR, incidence rate; HR, hazard ratio; PY, person-year; Ref., reference</p></table-wrap-foot></table-wrap>
</p><p id="Par24">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Associations between serum &#947;-glutamyl transferase (GGT) levels and lung-cancer development in female participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">GGT</th><th align="left" colspan="1" rowspan="1">N</th><th align="left" colspan="1" rowspan="1">Event</th><th align="left" colspan="1" rowspan="1">Duration, PY</th><th align="left" colspan="1" rowspan="1">IR, per 1000 PY</th><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Q1 (&#8804;&#8201;12 IU/L)</td><td align="left" colspan="1" rowspan="1">505,706</td><td align="left" colspan="1" rowspan="1">2,158</td><td align="left" colspan="1" rowspan="1">4,710,145</td><td align="left" colspan="1" rowspan="1">0.46</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q2 (13&#8211;16 IU/L)</td><td align="left" colspan="1" rowspan="1">517,483</td><td align="left" colspan="1" rowspan="1">2,653</td><td align="left" colspan="1" rowspan="1">4,818,311</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">1.20 (1.14, 1.27)</td><td align="left" colspan="1" rowspan="1">1.01 (0.95, 1.07)</td><td align="left" colspan="1" rowspan="1">1.00 (0.95, 1.06)</td><td align="left" colspan="1" rowspan="1">1.00 (0.95, 1.06)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q3 (17&#8211;23 IU/L)</td><td align="left" colspan="1" rowspan="1">503,525</td><td align="left" colspan="1" rowspan="1">3,193</td><td align="left" colspan="1" rowspan="1">4,678,340</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">1.49 (1.41, 1.57)</td><td align="left" colspan="1" rowspan="1">1.08 (1.02, 1.14)</td><td align="left" colspan="1" rowspan="1">1.06 (1.01, 1.12)</td><td align="left" colspan="1" rowspan="1">1.06 (1.00, 1.12)</td></tr><tr><td align="left" colspan="1" rowspan="1">Q4 (&#8805;&#8201;24 IU/L)</td><td align="left" colspan="1" rowspan="1">505,527</td><td align="left" colspan="1" rowspan="1">3,702</td><td align="left" colspan="1" rowspan="1">4,677,707</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">1.73 (1.64, 1.82)</td><td align="left" colspan="1" rowspan="1">1.17 (1.11, 1.23)</td><td align="left" colspan="1" rowspan="1">1.13 (1.07, 1.20)</td><td align="left" colspan="1" rowspan="1">1.13 (1.06, 1.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">D1 (&#8804;&#8201;10 IU/L)</td><td align="left" colspan="1" rowspan="1">241,473</td><td align="left" colspan="1" rowspan="1">950</td><td align="left" colspan="1" rowspan="1">2,249,188</td><td align="left" colspan="1" rowspan="1">0.42</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">D2 (11 IU/L)</td><td align="left" colspan="1" rowspan="1">126,817</td><td align="left" colspan="1" rowspan="1">529</td><td align="left" colspan="1" rowspan="1">1,181,330</td><td align="left" colspan="1" rowspan="1">0.45</td><td align="left" colspan="1" rowspan="1">1.06 (0.95, 1.18)</td><td align="left" colspan="1" rowspan="1">0.99 (0.89, 1.10)</td><td align="left" colspan="1" rowspan="1">0.98 (0.88, 1.09)</td><td align="left" colspan="1" rowspan="1">0.98 (0.88, 1.09)</td></tr><tr><td align="left" colspan="1" rowspan="1">D3 (12&#8211;13 IU/L)</td><td align="left" colspan="1" rowspan="1">276,938</td><td align="left" colspan="1" rowspan="1">1,362</td><td align="left" colspan="1" rowspan="1">2,579,670</td><td align="left" colspan="1" rowspan="1">0.53</td><td align="left" colspan="1" rowspan="1">1.25 (1.15, 1.36)</td><td align="left" colspan="1" rowspan="1">1.07 (0.99, 1.17)</td><td align="left" colspan="1" rowspan="1">1.07 (0.98, 1.16)</td><td align="left" colspan="1" rowspan="1">1.07 (0.98, 1.16)</td></tr><tr><td align="left" colspan="1" rowspan="1">D4 (14 IU/L)</td><td align="left" colspan="1" rowspan="1">135,550</td><td align="left" colspan="1" rowspan="1">723</td><td align="left" colspan="1" rowspan="1">1,261,790</td><td align="left" colspan="1" rowspan="1">0.57</td><td align="left" colspan="1" rowspan="1">1.36 (1.23, 1.49)</td><td align="left" colspan="1" rowspan="1">1.09 (0.99, 1.20)</td><td align="left" colspan="1" rowspan="1">1.08 (0.98, 1.19)</td><td align="left" colspan="1" rowspan="1">1.08 (0.98, 1.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">D5 (15&#8211;16 IU/L)</td><td align="left" colspan="1" rowspan="1">242,411</td><td align="left" colspan="1" rowspan="1">1,247</td><td align="left" colspan="1" rowspan="1">2,256,478</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">1.31 (1.20, 1.42)</td><td align="left" colspan="1" rowspan="1">1.00 (0.92, 1.09)</td><td align="left" colspan="1" rowspan="1">0.99 (0.91, 1.08)</td><td align="left" colspan="1" rowspan="1">0.99 (0.91, 1.07)</td></tr><tr><td align="left" colspan="1" rowspan="1">D6 (17&#8211;18 IU/L)</td><td align="left" colspan="1" rowspan="1">193,104</td><td align="left" colspan="1" rowspan="1">1,136</td><td align="left" colspan="1" rowspan="1">1,795,010</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">1.50 (1.37, 1.63)</td><td align="left" colspan="1" rowspan="1">1.07 (0.98, 1.17)</td><td align="left" colspan="1" rowspan="1">1.06 (0.97, 1.15)</td><td align="left" colspan="1" rowspan="1">1.05 (0.97, 1.15)</td></tr><tr><td align="left" colspan="1" rowspan="1">D7 (19&#8211;21 IU/L)</td><td align="left" colspan="1" rowspan="1">210,674</td><td align="left" colspan="1" rowspan="1">1,386</td><td align="left" colspan="1" rowspan="1">1,956,743</td><td align="left" colspan="1" rowspan="1">0.71</td><td align="left" colspan="1" rowspan="1">1.68 (1.54, 1.82)</td><td align="left" colspan="1" rowspan="1">1.14 (1.05, 1.23)</td><td align="left" colspan="1" rowspan="1">1.12 (1.03, 1.21)</td><td align="left" colspan="1" rowspan="1">1.11 (1.03, 1.21)</td></tr><tr><td align="left" colspan="1" rowspan="1">D8 (22&#8211;26 IU/L)</td><td align="left" colspan="1" rowspan="1">211,056</td><td align="left" colspan="1" rowspan="1">1,437</td><td align="left" colspan="1" rowspan="1">1,959,548</td><td align="left" colspan="1" rowspan="1">0.73</td><td align="left" colspan="1" rowspan="1">1.73 (1.60, 1.88)</td><td align="left" colspan="1" rowspan="1">1.12 (1.03, 1.22)</td><td align="left" colspan="1" rowspan="1">1.10 (1.01, 1.19)</td><td align="left" colspan="1" rowspan="1">1.09 (1.01, 1.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">D9 (27&#8211;36 IU/L)</td><td align="left" colspan="1" rowspan="1">191,118</td><td align="left" colspan="1" rowspan="1">1,398</td><td align="left" colspan="1" rowspan="1">1,771,500</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">1.87 (1.72, 2.03)</td><td align="left" colspan="1" rowspan="1">1.18 (1.09, 1.28)</td><td align="left" colspan="1" rowspan="1">1.15 (1.05, 1.25)</td><td align="left" colspan="1" rowspan="1">1.14 (1.05, 1.24)</td></tr><tr><td align="left" colspan="1" rowspan="1">D10 (&#8805;&#8201;37 IU/L)</td><td align="left" colspan="1" rowspan="1">203,100</td><td align="left" colspan="1" rowspan="1">1,538</td><td align="left" colspan="1" rowspan="1">1,873,246</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">1.94 (1.79, 2.11)</td><td align="left" colspan="1" rowspan="1">1.26 (1.16, 1.37)</td><td align="left" colspan="1" rowspan="1">1.21 (1.11, 1.32)</td><td align="left" colspan="1" rowspan="1">1.20 (1.10, 1.31)</td></tr></tbody></table><table-wrap-foot><p>Model 1: Non-adjusted</p><p>Model 2: Adjusted for age</p><p>Model 3: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, and chronic kidney disease</p><p>Model 4: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, chronic kidney disease, liver cirrhosis, viral hepatitis, alcohol use disorder, and metabolic syndrome</p><p>In the multivariate analyses, age and BMI were included as continuous variables</p><p>BMI, body mass index; CI, confidence interval; IR, incidence rate; HR, hazard ratio; PY, person-year; Ref., reference</p></table-wrap-foot></table-wrap>
</p><p id="Par25">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Association between serum &#947;-glutamyl transferase (GGT) levels and lung cancer incidence. (<bold>A</bold>) Cumulative incidence of lung cancer among males according to GGT level category in quartiles. (<bold>B</bold>) Cumulative incidence of lung cancer among females according to GGT level category in quartiles</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1917" position="float" orientation="portrait" xlink:href="12931_2025_3317_Fig2_HTML.jpg"/></fig>
</p><p id="Par26">These tendencies were consistently observed with increasing decile categories of serum GGT levels, resulting in the highest incidence rate (males: 1.38/1,000 PY; females: 0.82/1,000 PY) and risk (males: aHR1.57, 95% CI 1.48&#8211;1.67; females: aHR 1.20, 95% CI 1.10&#8211;1.31) in D10 (males: &#8805;93 IU/L; females: &#8805;37 IU/L). Restricted cubic spline curve also revealed a dose&#8211;response relationship between GGT levels and lung-cancer risk (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par27">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Association between serum &#947;-glutamyl transferase (GGT) levels and lung cancer risk demonstrated using a restricted cubic spline curve. (<bold>A</bold>) Males, (<bold>B</bold>) Females. Because the distribution of GGT levels did not meet the assumption of normality, a logarithmic transformation was applied to approximate a normal distribution prior to analysis. Accordingly, the X-axis in the figure represents log-transformed GGT values</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1939" position="float" orientation="portrait" xlink:href="12931_2025_3317_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec11"><title>Stratified analyses by age, smoking history, and alcohol consumption</title><p id="Par28">Tables&#160;<xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref> demonstrates stratified analyses by age (20&#8211;39, 40&#8211;64, and &#8805;&#8201;65 years), smoking status (never, former, and current smokers), smoking amount (never, 1&#8211;9, 10&#8211;19, &#8805;&#8201;20 pack-years), and alcohol consumption (non, mild, moderate, and heavy drinkers). Regarding age, lung cancer risk notably increased with GGT levels for individuals aged 40&#8211;64 and &#8805;&#8201;65 years. Regarding smoking status, the risk of lung cancer significantly increased with GGT levels for never (males) or former (females) smokers, but not for current smokers. Regarding smoking amount, the risk of lung cancer significantly increased with GGT levels for never or mild smokers (1&#8211;9 pack-years). Regarding alcohol consumption, lung cancer risk increased with GGT levels for non or mild drinkers but not for moderate or heavy drinkers.</p><p id="Par29">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Associations between serum &#947;-glutamyl transferase (GGT) level and lung-cancer development, stratified by age, smoking status, smoking amount, and alcohol consumption in male participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Subgroup</th><th align="left" colspan="1" rowspan="1">GGT</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" colspan="1" rowspan="1">Event</th><th align="left" colspan="1" rowspan="1">Duration, PY</th><th align="left" colspan="1" rowspan="1">IR, per 1000 PY</th><th align="left" colspan="1" rowspan="1">Model 3: aHR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">20&#8211;39 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">621,547</td><td char="." align="char" colspan="1" rowspan="1">440</td><td char="." align="char" colspan="1" rowspan="1">5,806,835</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">162,810</td><td char="." align="char" colspan="1" rowspan="1">134</td><td char="." align="char" colspan="1" rowspan="1">1,511,913</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">0.96 (0.79, 1.16)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;64 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">986,689</td><td char="." align="char" colspan="1" rowspan="1">9,033</td><td char="." align="char" colspan="1" rowspan="1">9,148,999</td><td char="." align="char" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">389,867</td><td char="." align="char" colspan="1" rowspan="1">4,168</td><td char="." align="char" colspan="1" rowspan="1">3,577,107</td><td char="." align="char" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1.14 (1.10, 1.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;65 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">209,309</td><td char="." align="char" colspan="1" rowspan="1">9,481</td><td char="." align="char" colspan="1" rowspan="1">1,801,721</td><td char="." align="char" colspan="1" rowspan="1">5.26</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">44,533</td><td char="." align="char" colspan="1" rowspan="1">2,472</td><td char="." align="char" colspan="1" rowspan="1">372,975</td><td char="." align="char" colspan="1" rowspan="1">6.63</td><td align="left" colspan="1" rowspan="1">1.31 (1.25, 1.37)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;&lt;&#8201;0.0001</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">601,102</td><td char="." align="char" colspan="1" rowspan="1">4,507</td><td char="." align="char" colspan="1" rowspan="1">5,545,013</td><td char="." align="char" colspan="1" rowspan="1">0.81</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">127,392</td><td char="." align="char" colspan="1" rowspan="1">1,180</td><td char="." align="char" colspan="1" rowspan="1">1,164,582</td><td char="." align="char" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">1.39 (1.30, 1.48)</td></tr><tr><td align="left" colspan="1" rowspan="1">Former</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">494,725</td><td char="." align="char" colspan="1" rowspan="1">5,813</td><td char="." align="char" colspan="1" rowspan="1">4,556,657</td><td char="." align="char" colspan="1" rowspan="1">1.28</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">155,785</td><td char="." align="char" colspan="1" rowspan="1">1,777</td><td char="." align="char" colspan="1" rowspan="1">1,429,112</td><td char="." align="char" colspan="1" rowspan="1">1.24</td><td align="left" colspan="1" rowspan="1">1.26 (1.19, 1.33)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">721,718</td><td char="." align="char" colspan="1" rowspan="1">8,634</td><td char="." align="char" colspan="1" rowspan="1">6,655,884</td><td char="." align="char" colspan="1" rowspan="1">1.30</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">314,033</td><td char="." align="char" colspan="1" rowspan="1">3,817</td><td char="." align="char" colspan="1" rowspan="1">2,868,301</td><td char="." align="char" colspan="1" rowspan="1">1.33</td><td align="left" colspan="1" rowspan="1">1.14 (1.09, 1.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;&lt;&#8201;0.0001</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking amount (pack-years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">601,102</td><td char="." align="char" colspan="1" rowspan="1">4,507</td><td char="." align="char" colspan="1" rowspan="1">5,545,013</td><td char="." align="char" colspan="1" rowspan="1">0.81</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">127,392</td><td char="." align="char" colspan="1" rowspan="1">1,180</td><td char="." align="char" colspan="1" rowspan="1">1,164,582</td><td char="." align="char" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">1.39 (1.30, 1.48)</td></tr><tr><td align="left" colspan="1" rowspan="1">1&#8211;9</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">477,685</td><td char="." align="char" colspan="1" rowspan="1">1,856</td><td char="." align="char" colspan="1" rowspan="1">4,441,139</td><td char="." align="char" colspan="1" rowspan="1">0.42</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">137,953</td><td char="." align="char" colspan="1" rowspan="1">598</td><td char="." align="char" colspan="1" rowspan="1">1,273,500</td><td char="." align="char" colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1">1.23 (1.12, 1.35)</td></tr><tr><td align="left" colspan="1" rowspan="1">10&#8211;19</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">357,943</td><td char="." align="char" colspan="1" rowspan="1">2,789</td><td char="." align="char" colspan="1" rowspan="1">3,310,490</td><td char="." align="char" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">146,077</td><td char="." align="char" colspan="1" rowspan="1">985</td><td char="." align="char" colspan="1" rowspan="1">1,342,486</td><td char="." align="char" colspan="1" rowspan="1">0.73</td><td align="left" colspan="1" rowspan="1">1.11 (1.03, 1.20)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;20</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">380,815</td><td char="." align="char" colspan="1" rowspan="1">9,802</td><td char="." align="char" colspan="1" rowspan="1">3,460,912</td><td char="." align="char" colspan="1" rowspan="1">2.83</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">185,788</td><td char="." align="char" colspan="1" rowspan="1">4,011</td><td char="." align="char" colspan="1" rowspan="1">1,681,427</td><td char="." align="char" colspan="1" rowspan="1">2.39</td><td align="left" colspan="1" rowspan="1">1.16 (1.12, 1.21)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;&lt;&#8201;0.0001</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Alcohol consumption</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">664,826</td><td char="." align="char" colspan="1" rowspan="1">9,609</td><td char="." align="char" colspan="1" rowspan="1">6,068,394</td><td char="." align="char" colspan="1" rowspan="1">1.58</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">94,213</td><td char="." align="char" colspan="1" rowspan="1">1,365</td><td char="." align="char" colspan="1" rowspan="1">850,108</td><td char="." align="char" colspan="1" rowspan="1">1.61</td><td align="left" colspan="1" rowspan="1">1.22 (1.15, 1.29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild (&lt;&#8201;10&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">558,934</td><td char="." align="char" colspan="1" rowspan="1">4,348</td><td char="." align="char" colspan="1" rowspan="1">5,182,068</td><td char="." align="char" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">124,542</td><td char="." align="char" colspan="1" rowspan="1">1,312</td><td char="." align="char" colspan="1" rowspan="1">1,142,004</td><td char="." align="char" colspan="1" rowspan="1">1.15</td><td align="left" colspan="1" rowspan="1">1.28 (1.21, 1.37)</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderate (10&#8211;19&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">296,622</td><td char="." align="char" colspan="1" rowspan="1">2,269</td><td char="." align="char" colspan="1" rowspan="1">2,753,000</td><td char="." align="char" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">129,064</td><td char="." align="char" colspan="1" rowspan="1">1,324</td><td char="." align="char" colspan="1" rowspan="1">1,185,127</td><td char="." align="char" colspan="1" rowspan="1">1.12</td><td align="left" colspan="1" rowspan="1">1.26 (1.17, 1.34)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy (&#8805;&#8201;20&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">297,163</td><td char="." align="char" colspan="1" rowspan="1">2,728</td><td char="." align="char" colspan="1" rowspan="1">2,754,092</td><td char="." align="char" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">249,391</td><td char="." align="char" colspan="1" rowspan="1">2,773</td><td char="." align="char" colspan="1" rowspan="1">2,284,756</td><td char="." align="char" colspan="1" rowspan="1">1.21</td><td align="left" colspan="1" rowspan="1">1.14 (1.08, 1.20)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;0.0189</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Model 3: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, and chronic kidney disease</p><p>In the multivariate analyses, age and BMI were included as continuous variables</p><p>IR, incidence rate; CI, confidence interval; HR, hazard ratio; PY, person-year; Ref., reference</p></table-wrap-foot></table-wrap>
</p><p id="Par30">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Association between serum &#947;-glutamyl transferase (GGT) level and lung cancer development, stratified by age, smoking status, smoking amount, and alcohol consumption in female participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Subgroup</th><th align="left" colspan="1" rowspan="1">GGT</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" colspan="1" rowspan="1">Event</th><th align="left" colspan="1" rowspan="1">Duration, PY</th><th align="left" colspan="1" rowspan="1">IR, per 1000 PY</th><th align="left" colspan="1" rowspan="1">Model 3: aHR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">20&#8211;39 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">406,447</td><td char="." align="char" colspan="1" rowspan="1">339</td><td char="." align="char" colspan="1" rowspan="1">3,795,780</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">59,459</td><td char="." align="char" colspan="1" rowspan="1">68</td><td char="." align="char" colspan="1" rowspan="1">552,734</td><td char="." align="char" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1">1.20 (0.93, 1.56)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;64 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">908,644</td><td char="." align="char" colspan="1" rowspan="1">4,643</td><td char="." align="char" colspan="1" rowspan="1">8,494,560</td><td char="." align="char" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">351,299</td><td char="." align="char" colspan="1" rowspan="1">2,213</td><td char="." align="char" colspan="1" rowspan="1">3,272,912</td><td char="." align="char" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">1.07 (1.02, 1.13)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;65 years</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">211,623</td><td char="." align="char" colspan="1" rowspan="1">3,022</td><td char="." align="char" colspan="1" rowspan="1">1,916,456</td><td char="." align="char" colspan="1" rowspan="1">1.58</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">94,769</td><td char="." align="char" colspan="1" rowspan="1">1,421</td><td char="." align="char" colspan="1" rowspan="1">852,061</td><td char="." align="char" colspan="1" rowspan="1">1.67</td><td align="left" colspan="1" rowspan="1">1.08 (1.02, 1.16)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;0.6778</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">1,457,783</td><td char="." align="char" colspan="1" rowspan="1">7,558</td><td char="." align="char" colspan="1" rowspan="1">13,567,895</td><td char="." align="char" colspan="1" rowspan="1">0.56</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">464,590</td><td char="." align="char" colspan="1" rowspan="1">3,295</td><td char="." align="char" colspan="1" rowspan="1">4,301,022</td><td char="." align="char" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">1.09 (1.04, 1.13)</td></tr><tr><td align="left" colspan="1" rowspan="1">Former</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">26,537</td><td char="." align="char" colspan="1" rowspan="1">106</td><td char="." align="char" colspan="1" rowspan="1">246,258</td><td char="." align="char" colspan="1" rowspan="1">0.43</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">10,927</td><td char="." align="char" colspan="1" rowspan="1">98</td><td char="." align="char" colspan="1" rowspan="1">100,591</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">1.71 (1.30, 2.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">42,394</td><td char="." align="char" colspan="1" rowspan="1">340</td><td char="." align="char" colspan="1" rowspan="1">392,643</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">30,010</td><td char="." align="char" colspan="1" rowspan="1">309</td><td char="." align="char" colspan="1" rowspan="1">276,094</td><td char="." align="char" colspan="1" rowspan="1">1.12</td><td align="left" colspan="1" rowspan="1">1.10 (0.94, 1.28)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;0.0063</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking amount (pack-years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">1,457,783</td><td char="." align="char" colspan="1" rowspan="1">7,558</td><td char="." align="char" colspan="1" rowspan="1">13,567,895</td><td char="." align="char" colspan="1" rowspan="1">0.56</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">464,590</td><td char="." align="char" colspan="1" rowspan="1">3,295</td><td char="." align="char" colspan="1" rowspan="1">4,301,022</td><td char="." align="char" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">1.09 (1.04, 1.14)</td></tr><tr><td align="left" colspan="1" rowspan="1">1&#8211;9</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">56,868</td><td char="." align="char" colspan="1" rowspan="1">208</td><td char="." align="char" colspan="1" rowspan="1">528,773</td><td char="." align="char" colspan="1" rowspan="1">0.39</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">29,660</td><td char="." align="char" colspan="1" rowspan="1">183</td><td char="." align="char" colspan="1" rowspan="1">274,002</td><td char="." align="char" colspan="1" rowspan="1">0.67</td><td align="left" colspan="1" rowspan="1">1.32 (1.08, 1.61)</td></tr><tr><td align="left" colspan="1" rowspan="1">10&#8211;19</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">8,025</td><td char="." align="char" colspan="1" rowspan="1">122</td><td char="." align="char" colspan="1" rowspan="1">73,743</td><td char="." align="char" colspan="1" rowspan="1">1.65</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">7,152</td><td char="." align="char" colspan="1" rowspan="1">101</td><td char="." align="char" colspan="1" rowspan="1">65,548</td><td char="." align="char" colspan="1" rowspan="1">1.54</td><td align="left" colspan="1" rowspan="1">0.96 (0.74, 1.26)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;20</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">4,038</td><td char="." align="char" colspan="1" rowspan="1">116</td><td char="." align="char" colspan="1" rowspan="1">36,385</td><td char="." align="char" colspan="1" rowspan="1">3.19</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">4,125</td><td char="." align="char" colspan="1" rowspan="1">123</td><td char="." align="char" colspan="1" rowspan="1">37,135</td><td char="." align="char" colspan="1" rowspan="1">3.31</td><td align="left" colspan="1" rowspan="1">1.15 (0.89, 1.48)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;0.2158</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Alcohol consumption</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">1,128,621</td><td char="." align="char" colspan="1" rowspan="1">6,854</td><td char="." align="char" colspan="1" rowspan="1">10,489,939</td><td char="." align="char" colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">359,254</td><td char="." align="char" colspan="1" rowspan="1">2,931</td><td char="." align="char" colspan="1" rowspan="1">3,319,106</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">1.08 (1.03, 1.12)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild (&lt;&#8201;10&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">320,337</td><td char="." align="char" colspan="1" rowspan="1">938</td><td char="." align="char" colspan="1" rowspan="1">2,990,747</td><td char="." align="char" colspan="1" rowspan="1">0.31</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">94,796</td><td char="." align="char" colspan="1" rowspan="1">515</td><td char="." align="char" colspan="1" rowspan="1">880,954</td><td char="." align="char" colspan="1" rowspan="1">0.58</td><td align="left" colspan="1" rowspan="1">1.22 (1.10, 1.36)</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderate (10&#8211;19&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">51,006</td><td char="." align="char" colspan="1" rowspan="1">142</td><td char="." align="char" colspan="1" rowspan="1">476,392</td><td char="." align="char" colspan="1" rowspan="1">0.30</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">28,240</td><td char="." align="char" colspan="1" rowspan="1">130</td><td char="." align="char" colspan="1" rowspan="1">262,059</td><td char="." align="char" colspan="1" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1">1.07 (0.84, 1.35)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy (&#8805;&#8201;20&#160;g/day)</td><td align="left" colspan="1" rowspan="1">Q1&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">26,750</td><td char="." align="char" colspan="1" rowspan="1">70</td><td char="." align="char" colspan="1" rowspan="1">249,720</td><td char="." align="char" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">23,237</td><td char="." align="char" colspan="1" rowspan="1">126</td><td char="." align="char" colspan="1" rowspan="1">215,588</td><td char="." align="char" colspan="1" rowspan="1">0.58</td><td align="left" colspan="1" rowspan="1">1.30 (0.97, 1.75)</td></tr><tr><td align="left" colspan="1" rowspan="1">P for interaction&#8201;=&#8201;0.1101</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Model 3: Adjusted for age, income, BMI, smoking, alcohol consumption, regular exercise, diabetes, hypertension, dyslipidemia, and chronic kidney disease</p><p>In the multivariate analyses, age and BMI were included as continuous variables</p><p>IR, incidence rate; CI, confidence interval; HR, hazard ratio; PY, person-year; Ref., reference</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par31">In this nationwide population-based retrospective cohort study including more than 4&#160;million individuals, we examined associations between serum GGT levels and lung-cancer development. Higher serum GGT levels were positively associated with progressively higher risks of lung cancer development. In the stratified analyses, the risk of lung cancer was more prominent among middle-aged or older adults, never or former smokers, and non or mild drinkers. Therefore, our findings suggest that elevated serum GGT levels may predict a higher risk of lung cancer development.</p><p id="Par32">Previous observational studies found a positive association between lung cancer and elevated serum GGT levels [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]; however, in some of them, an association was observed only in males but not in females [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Cigarette smoking and alcohol consumption, prevalent lifestyle behaviors in males, can synergistically increase serum GGT levels [<xref ref-type="bibr" rid="CR18">18</xref>]. Thus, these factors may represent potential confounders in the evaluation of lung cancer risk. In our study, most female participants were never smokers (&gt;&#8201;90%) or non-alcohol drinkers (&gt;&#8201;70%). Furthermore, after adjusting for cigarette smoking and alcohol consumption, our multivariate regression model revealed a significant association between serum GGT level and lung cancer development. These findings underscore the significant association between serum GGT level and lung cancer, and warrant investigation of the pathophysiological mechanisms involved other than lifestyle behaviors such as cigarette smoking or alcohol consumption.</p><p id="Par33">The relationship between elevated serum GGT level and lung cancer can be explained through some hypotheses. First, GGT exerts pro-oxidant effects and may contribute to oxidative stress during cancer progression, such as cell proliferation or apoptosis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Elevated serum GGT levels may reflect oxidative stress or chronic inflammation, which can contribute to carcinogenesis and cancer progression [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. GGT may promote cancer cell growth through an increased supply of cysteine and protect against apoptosis through upregulation of poly(adenosine diphosphate-ribose) polymerase activity [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, GGT is a key enzyme in serum glutathione metabolism as an antioxidant defense mechanism [<xref ref-type="bibr" rid="CR4">4</xref>], which is also related with reactive oxygen species-induced apoptosis in cancer cells [<xref ref-type="bibr" rid="CR30">30</xref>]. In lung epithelial cells, GGT is secreted into the epithelial lining fluid during inflammation, which may in turn increase epithelial damage by decreasing glutathione [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Second, elevated serum GGT levels are linked to obesity or metabolic syndrome [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], which are also risk factors of lung cancer [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In our study, higher serum GGT levels were associated with higher BMI, greater waist circumference, and higher total cholesterol or fasting glucose levels. These findings imply a potential relationship between serum GGT levels and obesity or metabolic syndrome in our cohort; however, a significant association between serum GGT levels and lung cancer was observed after adjusting for metabolic syndrome. Thus, the pathophysiologic role of metabolic disorders in lung cancer warrants further investigation.</p><p id="Par34">In the subgroup analysis stratified by age, the association between serum GGT level and lung cancer was significant among middle-aged (40&#8211;64 years) and older adults (&#8805;&#8201;65 years), but not among young adults (20&#8211;39 years). However, we also noted that cases of lung cancer were far less diagnosed (&lt;&#8201;10% of total) in this age group than those in other groups. Thus, further research is required in this age group to elucidate the association between serum GGT levels and lung cancer incidence.</p><p id="Par35">Regarding lifestyle behaviors such as smoking or alcohol consumption, we found that lung cancer risk notably increased with GGT levels among never or former smokers and among non or mild drinkers. These findings can be explained by the hypotheses that elevated serum GGT levels in current smokers or in moderate to heavy alcohol drinkers may be attributed to smoking or alcohol consumption, rather than other potential mechanisms. Thus, physicians should be cautious about elevated serum GGT levels in patients lacking a history of smoking or heavy alcohol consumption.</p><p id="Par36">This study had some limitations. First, as the NHE is a screening test for the general healthy population and does not employ abdominal ultrasonography, conditions in which serum GGT levels are frequently elevated, such as non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease, could not be evaluated. However, we designed our regression model adjusting for other covariates potentially associated with altered GGT levels, such as BMI, alcohol consumption, and dyslipidemia. In addition, we adjusted for chronic liver conditions, including liver cirrhosis, viral hepatitis, and alcohol-use disorder. Second, as the NHE test is a voluntary program, many participants lacked consecutive participation in subsequent health examinations; thus, we could not evaluate longitudinal changes in serum GGT levels. As described previously, repetitive measurement of serum GGT may be useful to identify individuals with a higher risk of lung cancer [<xref ref-type="bibr" rid="CR9">9</xref>]. Third, as this was an observational retrospective study, the association between serum GGT levels and lung cancer risk might not be causal and should be cautiously interpreted. Elevated serum GGT levels may be an epiphenomenon observed in populations with other potential risk factors of lung cancer. Nevertheless, our results underscore that elevated serum GGT levels may predict an increased risk of lung cancer development. Meanwhile, it should not be overlooked that lung cancer development is influenced by complex interactions among multiple proteins, cytokines, and signaling pathways.</p></sec><sec id="Sec13"><title>Conclusions</title><p id="Par37">This study found that increasing levels of serum GGT were associated with an increasing risk of lung cancer development. These associations were more prominent in middle-aged or older adults, never or former smokers, and non or mild alcohol drinkers. In clinical practice, attending physicians should be cautious of GGT levels and consider further examinations for lung cancer diagnosis in individuals with elevated serum GGT levels in the absence of other potential metabolic causes.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Sei Won Lee and Kyungdo Han contributed equally to this work as corresponding authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Chiwook Chung, Kyu Na Lee, Dong Wook Shin, Sei Won Lee, and Kyungdo Han conceived and designed the study. Kyu Na Lee and Kyungdo Han contributed to data collection and analysis. Chiwook Chung, Dong Wook Shin, Sei Won Lee, and Kyungdo Han contributed to data interpretation and drafted the manuscript. All authors revised and approved the final manuscript. All authors accept responsibility for the accuracy of the content in the final manuscript. Generative artificial intelligence was not used in any portion of the manuscript writing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2023-NR077159), the Bio&amp;Medical Technology Development Program of the NRF funded by the MSIT (RS-2022-NR067421 and RS-2023-00222687), and the National Institute of Health research project (2024ER080601).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par38">The study protocol was approved by the Institutional Review Board of the Asan Medical Center, Seoul, Republic of Korea (approval no. 2024&#8201;&#8722;&#8201;0990). The requirement for informed consent was waived, as it was a retrospective study and the data used were anonymized. This study complied with the guidelines stipulated in the Declaration of Helsinki, and all methods were performed in accordance with the relevant guidelines.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par39">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par40">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>GGT</term><def><p id="Par41">&#947;-glutamyl transferase</p></def></def-item><def-item><term>aHR</term><def><p id="Par42">Adjusted hazard ratio</p></def></def-item><def-item><term>CI</term><def><p id="Par43">Confidence interval</p></def></def-item><def-item><term>NHIS</term><def><p id="Par44">Korean National Health Insurance Service</p></def></def-item><def-item><term>NHE</term><def><p id="Par45">National health examination</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par46">International Classification of Diseases, 10th Revision</p></def></def-item><def-item><term>BMI</term><def><p id="Par47">Body mass index</p></def></def-item><def-item><term>PY</term><def><p id="Par48">Person-years</p></def></def-item><def-item><term>SD</term><def><p id="Par49">Standard deviation</p></def></def-item><def-item><term>Q1&#8211;Q4</term><def><p id="Par50">Quartiles 1&#8211;4 (low to high)</p></def></def-item><def-item><term>D1&#8211;D10</term><def><p id="Par51">Deciles 1&#8211;10 (low to high)</p></def></def-item><def-item><term>Cyfra 21&#8201;&#8722;&#8201;1</term><def><p id="Par52">Cytokeratin 19 fragment</p></def></def-item><def-item><term>NSE</term><def><p id="Par53">Neuron-specific enolase</p></def></def-item><def-item><term>ProGRP</term><def><p id="Par54">Progastrin-releasing peptide</p></def></def-item><def-item><term>SCC</term><def><p id="Par55">Squamous cell carcinoma antigen</p></def></def-item><def-item><term>CEA</term><def><p id="Par56">Carcinoembryonic antigen</p></def></def-item><def-item><term>SAS</term><def><p id="Par57">Statistical Analysis Software</p></def></def-item><def-item><term>MSIT</term><def><p id="Par58">Ministry of Science and ICT (Korea)</p></def></def-item><def-item><term>NRF</term><def><p id="Par59">National Research Foundation of Korea</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thandra</surname><given-names>KC</given-names></name><name name-style="western"><surname>Barsouk</surname><given-names>A</given-names></name><name name-style="western"><surname>Saginala</surname><given-names>K</given-names></name><name name-style="western"><surname>Aluru</surname><given-names>JS</given-names></name><name name-style="western"><surname>Barsouk</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology of lung cancer</article-title><source>Contemp Oncol (Pozn)</source><year>2021</year><volume>25</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">33911981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/wo.2021.103829</pub-id><pub-id pub-id-type="pmcid">PMC8063897</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45&#8211;52.<pub-id pub-id-type="pmid">33911981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/wo.2021.103829</pub-id><pub-id pub-id-type="pmcid">PMC8063897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>KW</given-names></name><name name-style="western"><surname>Won</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><name name-style="western"><surname>Kong</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Im</surname><given-names>JS</given-names></name><name name-style="western"><surname>Seo</surname><given-names>HG</given-names></name></person-group><article-title>Prediction of Cancer incidence and mortality in korea, 2021</article-title><source>Cancer Res Treat</source><year>2021</year><volume>53</volume><fpage>316</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">33735558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2021.290</pub-id><pub-id pub-id-type="pmcid">PMC8053854</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jung KW, Won YJ, Hong S, Kong HJ, Im JS, Seo HG. Prediction of Cancer incidence and mortality in korea, 2021. Cancer Res Treat. 2021;53:316&#8211;22.<pub-id pub-id-type="pmid">33735558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2021.290</pub-id><pub-id pub-id-type="pmcid">PMC8053854</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name></person-group><article-title>Tumor markers in detection of lung cancer</article-title><source>Adv Clin Chem</source><year>2006</year><volume>42</volume><fpage>1</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17131623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-2423(06)42001-1</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem. 2006;42:1&#8211;41.<pub-id pub-id-type="pmid">17131623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-2423(06)42001-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brennan</surname><given-names>PN</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>JF</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name></person-group><article-title>Gamma-Glutamyl transferase (gamma-GT) - an old dog with new tricks?</article-title><source>Liver Int</source><year>2022</year><volume>42</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">34775657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15099</pub-id><pub-id pub-id-type="pmcid">PMC11165564</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Brennan PN, Dillon JF, Tapper EB. Gamma-Glutamyl transferase (gamma-GT) - an old dog with new tricks? Liver Int. 2022;42:9&#8211;15.<pub-id pub-id-type="pmid">34775657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15099</pub-id><pub-id pub-id-type="pmcid">PMC11165564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Belcastro</surname><given-names>E</given-names></name><name name-style="western"><surname>Dominici</surname><given-names>S</given-names></name><name name-style="western"><surname>Maellaro</surname><given-names>E</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name></person-group><article-title>The dark side of gamma-glutamyltransferase (GGT): pathogenic effects of an &#8216;antioxidant&#8217; enzyme</article-title><source>Free Radic Biol Med</source><year>2020</year><volume>160</volume><fpage>807</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">32916278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2020.09.005</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. The dark side of gamma-glutamyltransferase (GGT): pathogenic effects of an &#8216;antioxidant&#8217; enzyme. Free Radic Biol Med. 2020;160:807&#8211;19.<pub-id pub-id-type="pmid">32916278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2020.09.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Franzini</surname><given-names>M</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name></person-group><article-title>Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting</article-title><source>Anticancer Res</source><year>2010</year><volume>30</volume><fpage>1169</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">20530424</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169&#8211;81.<pub-id pub-id-type="pmid">20530424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Giommarelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Gamma-glutamyltransferase, redox regulation and cancer drug resistance</article-title><source>Curr Opin Pharmacol</source><year>2007</year><volume>7</volume><fpage>360</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17613273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2007.04.004</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F. Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol. 2007;7:360&#8211;6.<pub-id pub-id-type="pmid">17613273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2007.04.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hemelrijck</surname><given-names>M</given-names></name><name name-style="western"><surname>Jassem</surname><given-names>W</given-names></name><name name-style="western"><surname>Walldius</surname><given-names>G</given-names></name><name name-style="western"><surname>Fentiman</surname><given-names>IS</given-names></name><name name-style="western"><surname>Hammar</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS study</article-title><source>Eur J Cancer</source><year>2011</year><volume>47</volume><fpage>2033</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21486691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2011.03.010</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Van Hemelrijck M, Jassem W, Walldius G, Fentiman IS, Hammar N, Lambe M, et al. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS study. Eur J Cancer. 2011;47:2033&#8211;41.<pub-id pub-id-type="pmid">21486691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2011.03.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>KD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name></person-group><article-title>Determining the association between repeatedly elevated serum gamma-glutamyltransferase levels and risk of respiratory cancer: A nationwide population-based cohort study</article-title><source>Cancer Med</source><year>2021</year><volume>10</volume><fpage>1366</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">33638317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3735</pub-id><pub-id pub-id-type="pmcid">PMC7925999</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lee YJ, Han KD, Kim DH, Lee CH. Determining the association between repeatedly elevated serum gamma-glutamyltransferase levels and risk of respiratory cancer: A nationwide population-based cohort study. Cancer Med. 2021;10:1366&#8211;76.<pub-id pub-id-type="pmid">33638317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3735</pub-id><pub-id pub-id-type="pmcid">PMC7925999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strasak</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>RM</given-names></name><name name-style="western"><surname>Klenk</surname><given-names>J</given-names></name><name name-style="western"><surname>Hilbe</surname><given-names>W</given-names></name><name name-style="western"><surname>Oberaigner</surname><given-names>W</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women</article-title><source>Int J Cancer</source><year>2008</year><volume>123</volume><fpage>1902</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18688855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23714</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Strasak AM, Pfeiffer RM, Klenk J, Hilbe W, Oberaigner W, Gregory M, et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int J Cancer. 2008;123:1902&#8211;6.<pub-id pub-id-type="pmid">18688855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strasak</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>K</given-names></name><name name-style="western"><surname>Brant</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Hilbe</surname><given-names>W</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>M</given-names></name><name name-style="western"><surname>Oberaigner</surname><given-names>W</given-names></name><etal/></person-group><article-title>Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>3970</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18483283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-07-6686</pub-id><pub-id pub-id-type="pmcid">PMC5955388</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Strasak AM, Rapp K, Brant LJ, Hilbe W, Gregory M, Oberaigner W, et al. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res. 2008;68:3970&#8211;7.<pub-id pub-id-type="pmid">18483283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-07-6686</pub-id><pub-id pub-id-type="pmcid">PMC5955388</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>Y</given-names></name><name name-style="western"><surname>Son</surname><given-names>DK</given-names></name><name name-style="western"><surname>Yun</surname><given-names>YD</given-names></name><name name-style="western"><surname>Jee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Samet</surname><given-names>JM</given-names></name></person-group><article-title>gamma-Glutamyltransferase and cancer risk: the Korean cancer prevention study</article-title><source>Int J Cancer</source><year>2016</year><volume>138</volume><fpage>311</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26111622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29659</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Mok Y, Son DK, Yun YD, Jee SH, Samet JM. gamma-Glutamyltransferase and cancer risk: the Korean cancer prevention study. Int J Cancer. 2016;138:311&#8211;9.<pub-id pub-id-type="pmid">26111622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozkaya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yazici</surname><given-names>O</given-names></name></person-group><article-title>Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer</article-title><source>Expert Rev Mol Diagn</source><year>2019</year><volume>19</volume><fpage>267</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">30722710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737159.2019.1579644</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bozkaya Y, Yazici O. Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Expert Rev Mol Diagn. 2019;19:267&#8211;72.<pub-id pub-id-type="pmid">30722710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737159.2019.1579644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ozkan</surname><given-names>D</given-names></name><name name-style="western"><surname>Kankoc</surname><given-names>A</given-names></name><name name-style="western"><surname>Tombul</surname><given-names>I</given-names></name><name name-style="western"><surname>Celik</surname><given-names>A</given-names></name><name name-style="western"><surname>Kurul</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Is Gamma-Glutamyl transferase a prognostic Indicator for Early-Stage lung Cancer treated surgically??</article-title><source>Wiad Lek</source><year>2021</year><volume>74</volume><fpage>1804</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">34537724</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sayan M, Ozkan D, Kankoc A, Tombul I, Celik A, Kurul IC, et al. Is Gamma-Glutamyl transferase a prognostic Indicator for Early-Stage lung Cancer treated surgically?? Wiad Lek. 2021;74:1804&#8211;8.<pub-id pub-id-type="pmid">34537724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>SM</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DW</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>The associations of aspirin, statins, and Metformin with lung Cancer risk and related mortality: A Time-Dependent analysis of Population-Based nationally representative data</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">32950701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2020.08.021</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kang J, Jeong SM, Shin DW, Cho M, Cho JH, Kim J. The associations of aspirin, statins, and Metformin with lung Cancer risk and related mortality: A Time-Dependent analysis of Population-Based nationally representative data. J Thorac Oncol. 2021;16:76&#8211;88.<pub-id pub-id-type="pmid">32950701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2020.08.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>MS</given-names></name><name name-style="western"><surname>Park</surname><given-names>M</given-names></name><name name-style="western"><surname>Back</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>GH</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><etal/></person-group><article-title>Validation of Cancer diagnosis based on the National health insurance service database versus the National Cancer registry database in Korea</article-title><source>Cancer Res Treat</source><year>2022</year><volume>54</volume><fpage>352</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">34353000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2021.044</pub-id><pub-id pub-id-type="pmcid">PMC9016317</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Yang MS, Park M, Back JH, Lee GH, Shin JH, Kim K, et al. Validation of Cancer diagnosis based on the National health insurance service database versus the National Cancer registry database in Korea. Cancer Res Treat. 2022;54:352&#8211;61.<pub-id pub-id-type="pmid">34353000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2021.044</pub-id><pub-id pub-id-type="pmcid">PMC9016317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>J</given-names></name><name name-style="western"><surname>Malvezzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Negri</surname><given-names>E</given-names></name><name name-style="western"><surname>La Vecchia</surname><given-names>C</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name></person-group><article-title>Risk factors for lung cancer worldwide</article-title><source>Eur Respir J</source><year>2016</year><volume>48</volume><fpage>889</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">27174888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00359-2016</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889&#8211;902.<pub-id pub-id-type="pmid">27174888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00359-2016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Geng</surname><given-names>H</given-names></name><name name-style="western"><surname>Bian</surname><given-names>Y</given-names></name></person-group><article-title>Effects of smoking, and drinking on serum Gamma-Glutamyl transferase levels using physical examination data: A Cross-Sectional study in Northwest China</article-title><source>Int J Gen Med</source><year>2021</year><volume>14</volume><fpage>1301</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33883928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJGM.S301900</pub-id><pub-id pub-id-type="pmcid">PMC8055286</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zhang Z, Ma L, Geng H, Bian Y. Effects of smoking, and drinking on serum Gamma-Glutamyl transferase levels using physical examination data: A Cross-Sectional study in Northwest China. Int J Gen Med. 2021;14:1301&#8211;9.<pub-id pub-id-type="pmid">33883928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJGM.S301900</pub-id><pub-id pub-id-type="pmcid">PMC8055286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheol Seong</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YY</given-names></name><name name-style="western"><surname>Khang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Heon Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Data resource profile: the National health information database of the National health insurance service in South Korea</article-title><source>Int J Epidemiol</source><year>2017</year><volume>46</volume><fpage>799</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">27794523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyw253</pub-id><pub-id pub-id-type="pmcid">PMC5837262</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the National health information database of the National health insurance service in South Korea. Int J Epidemiol. 2017;46:799&#8211;800.<pub-id pub-id-type="pmid">27794523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyw253</pub-id><pub-id pub-id-type="pmcid">PMC5837262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seong</surname><given-names>SC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YY</given-names></name><name name-style="western"><surname>Park</surname><given-names>SK</given-names></name><name name-style="western"><surname>Khang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HC</given-names></name><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Cohort profile: the National health insurance Service-National health screening cohort (NHIS-HEALS) in Korea</article-title><source>BMJ Open</source><year>2017</year><volume>7</volume><fpage>e016640</fpage><pub-id pub-id-type="pmid">28947447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2017-016640</pub-id><pub-id pub-id-type="pmcid">PMC5623538</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National health insurance Service-National health screening cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7:e016640.<pub-id pub-id-type="pmid">28947447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2017-016640</pub-id><pub-id pub-id-type="pmcid">PMC5623538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>Cohort profile: the National health insurance Service-National sample cohort (NHIS-NSC), South Korea</article-title><source>Int J Epidemiol</source><year>2017</year><volume>46</volume><fpage>e15</fpage><pub-id pub-id-type="pmid">26822938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyv319</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National health insurance Service-National sample cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46:e15.<pub-id pub-id-type="pmid">26822938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyv319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>DW</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B</given-names></name></person-group><article-title>National general health screening program in korea: history, current status, and future direction</article-title><source>Precis Future Med</source><year>2022</year><volume>6</volume><fpage>9</fpage><lpage>31</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Shin DW, Cho J, Park JH, Cho B. National general health screening program in korea: history, current status, and future direction. Precis Future Med. 2022;6:9&#8211;31.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piercy</surname><given-names>KL</given-names></name><name name-style="western"><surname>Troiano</surname><given-names>RP</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>RM</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Fulton</surname><given-names>JE</given-names></name><name name-style="western"><surname>Galuska</surname><given-names>DA</given-names></name><etal/></person-group><article-title>The physical activity guidelines for Americans</article-title><source>JAMA</source><year>2018</year><volume>320</volume><fpage>2020</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">30418471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.14854</pub-id><pub-id pub-id-type="pmcid">PMC9582631</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for Americans. JAMA. 2018;320:2020&#8211;8.<pub-id pub-id-type="pmid">30418471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.14854</pub-id><pub-id pub-id-type="pmcid">PMC9582631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>IY</given-names></name><name name-style="western"><surname>Koo</surname><given-names>HY</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KN</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M</given-names></name><name name-style="western"><surname>Jin</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Metabolic syndrome and the risk of abdominal aortic aneurysm: A nationwide cohort study</article-title><source>Atherosclerosis</source><year>2023</year><volume>386</volume><fpage>117329</fpage><pub-id pub-id-type="pmid">37839934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2023.117329</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Cho IY, Koo HY, Han K, Lee KN, Cho M, Jin SM, et al. Metabolic syndrome and the risk of abdominal aortic aneurysm: A nationwide cohort study. Atherosclerosis. 2023;386:117329.<pub-id pub-id-type="pmid">37839934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2023.117329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cho</surname><given-names>IY</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B</given-names></name><etal/></person-group><article-title>Association between metabolic syndrome and risk of esophageal cancer: a nationwide Population-Based study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2022</year><volume>31</volume><fpage>2228</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">36166509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-22-0703</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lee JE, Han K, Yoo J, Yeo Y, Cho IY, Cho B, et al. Association between metabolic syndrome and risk of esophageal cancer: a nationwide Population-Based study. Cancer Epidemiol Biomarkers Prev. 2022;31:2228&#8211;36.<pub-id pub-id-type="pmid">36166509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-22-0703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filaire</surname><given-names>E</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>C</given-names></name><name name-style="western"><surname>Galvaing</surname><given-names>G</given-names></name><name name-style="western"><surname>Aubreton</surname><given-names>S</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>H</given-names></name><name name-style="western"><surname>Richard</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lung cancer: what are the links with oxidative stress, physical activity and nutrition</article-title><source>Lung Cancer</source><year>2013</year><volume>82</volume><fpage>383</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24161719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2013.09.009</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Filaire E, Dupuis C, Galvaing G, Aubreton S, Laurent H, Richard R, et al. Lung cancer: what are the links with oxidative stress, physical activity and nutrition. Lung Cancer. 2013;82:383&#8211;9.<pub-id pub-id-type="pmid">24161719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2013.09.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>del Bello</surname><given-names>B</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Comporti</surname><given-names>M</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>Maellaro</surname><given-names>E</given-names></name></person-group><article-title>Hydrogen peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells</article-title><source>FASEB J</source><year>1999</year><volume>13</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">9872931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fasebj.13.1.69</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">del Bello B, Paolicchi A, Comporti M, Pompella A, Maellaro E. Hydrogen peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells. FASEB J. 1999;13:69&#8211;79.<pub-id pub-id-type="pmid">9872931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fasebj.13.1.69</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzini</surname><given-names>M</given-names></name><name name-style="western"><surname>Corti</surname><given-names>A</given-names></name><name name-style="western"><surname>Lorenzini</surname><given-names>E</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pompella</surname><given-names>A</given-names></name><name name-style="western"><surname>De Cesare</surname><given-names>M</given-names></name><etal/></person-group><article-title>Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>2623</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16928443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2006.04.016</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Franzini M, Corti A, Lorenzini E, Paolicchi A, Pompella A, De Cesare M, et al. Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. Eur J Cancer. 2006;42:2623&#8211;30.<pub-id pub-id-type="pmid">16928443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2006.04.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanigan</surname><given-names>MH</given-names></name></person-group><article-title>Gamma-glutamyl transpeptidase: redox regulation and drug resistance</article-title><source>Adv Cancer Res</source><year>2014</year><volume>122</volume><fpage>103</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">24974180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-420117-0.00003-7</pub-id><pub-id pub-id-type="pmcid">PMC4388159</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103&#8211;41.<pub-id pub-id-type="pmid">24974180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-420117-0.00003-7</pub-id><pub-id pub-id-type="pmcid">PMC4388159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>WH</given-names></name></person-group><article-title>MAPK inhibitors, particularly the JNK inhibitor, increase cell death effects in H2O2-treated lung cancer cells via increased superoxide anion and glutathione depletion</article-title><source>Oncol Rep</source><year>2018</year><volume>39</volume><fpage>860</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">29207156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2017.6107</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Park WH. MAPK inhibitors, particularly the JNK inhibitor, increase cell death effects in H2O2-treated lung cancer cells via increased superoxide anion and glutathione depletion. Oncol Rep. 2018;39:860&#8211;70.<pub-id pub-id-type="pmid">29207156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2017.6107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowry</surname><given-names>MH</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>BP</given-names></name><name name-style="western"><surname>Jean</surname><given-names>JC</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hughey</surname><given-names>RP</given-names></name><name name-style="western"><surname>Cruikshank</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Lung lining fluid glutathione attenuates IL-13-induced asthma</article-title><source>Am J Respir Cell Mol Biol</source><year>2008</year><volume>38</volume><fpage>509</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">18063838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2007-0128OC</pub-id><pub-id pub-id-type="pmcid">PMC2335334</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lowry MH, McAllister BP, Jean JC, Brown LA, Hughey RP, Cruikshank WW, et al. Lung lining fluid glutathione attenuates IL-13-induced asthma. Am J Respir Cell Mol Biol. 2008;38:509&#8211;16.<pub-id pub-id-type="pmid">18063838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2007-0128OC</pub-id><pub-id pub-id-type="pmcid">PMC2335334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuzova</surname><given-names>M</given-names></name><name name-style="western"><surname>Jean</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hughey</surname><given-names>RP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LA</given-names></name><name name-style="western"><surname>Cruikshank</surname><given-names>WW</given-names></name><name name-style="western"><surname>Hiratake</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibiting lung lining fluid glutathione metabolism with GGsTop as a novel treatment for asthma</article-title><source>Front Pharmacol</source><year>2014</year><volume>5</volume><fpage>179</fpage><pub-id pub-id-type="pmid">25132819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2014.00179</pub-id><pub-id pub-id-type="pmcid">PMC4116799</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tuzova M, Jean JC, Hughey RP, Brown LA, Cruikshank WW, Hiratake J, et al. Inhibiting lung lining fluid glutathione metabolism with GGsTop as a novel treatment for asthma. Front Pharmacol. 2014;5:179.<pub-id pub-id-type="pmid">25132819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2014.00179</pub-id><pub-id pub-id-type="pmcid">PMC4116799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stranges</surname><given-names>S</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>JM</given-names></name><name name-style="western"><surname>Muti</surname><given-names>P</given-names></name><name name-style="western"><surname>Freudenheim</surname><given-names>JL</given-names></name><name name-style="western"><surname>Farinaro</surname><given-names>E</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M</given-names></name><etal/></person-group><article-title>Body fat distribution, relative weight, and liver enzyme levels: a population-based study</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><fpage>754</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14999694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.20149</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39:754&#8211;63.<pub-id pub-id-type="pmid">14999694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.20149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name><name name-style="western"><surname>Hyon</surname><given-names>DS</given-names></name><name name-style="western"><surname>Huh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Han</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Association between serum Gamma-Glutamyltransferase and prevalence of metabolic syndrome using data from the Korean genome and epidemiology study</article-title><source>Endocrinol Metab (Seoul)</source><year>2019</year><volume>34</volume><fpage>390</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">31884739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2019.34.4.390</pub-id><pub-id pub-id-type="pmcid">PMC6935781</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Lee MY, Hyon DS, Huh JH, Kim HK, Han SK, Kim JY, et al. Association between serum Gamma-Glutamyltransferase and prevalence of metabolic syndrome using data from the Korean genome and epidemiology study. Endocrinol Metab (Seoul). 2019;34:390&#8211;7.<pub-id pub-id-type="pmid">31884739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2019.34.4.390</pub-id><pub-id pub-id-type="pmcid">PMC6935781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Hidayat K, Du X, Chen G, Shi M, Shi B. Abdominal obesity and lung Cancer risk: systematic review and Meta-Analysis of prospective studies. Nutrients. 2016;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu8120810</pub-id><pub-id pub-id-type="pmcid">PMC5188465</pub-id><pub-id pub-id-type="pmid">27983672</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Cao</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dimou</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>JB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Association of metabolic syndrome with risk of lung cancer: A Population-Based prospective cohort study</article-title><source>Chest</source><year>2024</year><volume>165</volume><fpage>213</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">37572975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chest.2023.08.003</pub-id><pub-id pub-id-type="pmcid">PMC10790176</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Li M, Cao SM, Dimou N, Wu L, Li JB, Yang J. Association of metabolic syndrome with risk of lung cancer: A Population-Based prospective cohort study. Chest. 2024;165:213&#8211;23.<pub-id pub-id-type="pmid">37572975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chest.2023.08.003</pub-id><pub-id pub-id-type="pmcid">PMC10790176</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>